<div class="hlFld-Fulltext">
<div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="boxed-text-float" id="d3e430">
<h2 class="article-section__title section__title" id="d3e432">Clinical Perspective</h2>
<h3 class="article-section__title to-section " id="d3e437">What Is New?</h3>
<ul class="NLM_list-list_type-bullet">
<li><p class="inline">In
 this post hoc subgroup analysis of the LEADER trial (Liraglutide Effect
 and Action in Diabetes: Evaluation of CV Outcome Results), liraglutide 
reduced the risk of major adverse cardiovascular events and all-cause 
mortality compared with placebo in patients with chronic kidney disease 
(CKD) defined as estimated glomerular filtration rate &lt;60 mL/min/1.73
 m<sup>2</sup>.</p></li>
<li><p class="inline">Liraglutide also reduced 
the risk of major adverse cardiovascular events in patients with 
albuminuria, defined as urinary albumin-to-creatinine ratio &gt;30 mg/g 
(micro- and macroalbuminuria).</p></li>
<li><p class="inline">The overall
 risk of adverse events did not differ between liraglutide- and 
placebo-treated patients either with or without CKD in the LEADER trial.</p></li>
</ul>
<h3 class="article-section__title to-section " id="d3e461">What Are the Clinical Implications?</h3>
<ul class="NLM_list-list_type-bullet">
<li><p class="inline">Liraglutide
 may be considered as a therapeutic option for patients with type 2 
diabetes mellitus with or at high risk for atherosclerotic 
cardiovascular disease who also have CKD.</p></li>
<li><p class="inline">The
 present results demonstrate that the results of the LEADER trial on 
cardiovascular efficacy and safety of liraglutide apply to patients with
 CKD, which is clinically important given that those patients with type 2
 diabetes mellitus and CKD have a high cardiovascular risk burden and 
few options for antihyperglycemic therapies.</p></li>
</ul>
</div>
<h3 class="article-section__title to-section " id="d3e479">Introduction</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Type
 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) are closely
 associated. Diabetic kidney disease is the most common cause of CKD and
 affects ≈40% of patients with T2DM.<sup><a data-tab="pane-pcw-references" href="#R1" id="R1R" class="tab-link">1</a></sup> Patients with diabetic kidney disease are at substantially increased risk of cardiovascular (CV) morbidity and mortality,<sup><a data-tab="pane-pcw-references" href="#R1" id="R1R" class="tab-link">1</a></sup> and most die from CV disease before reaching end-stage kidney disease or requiring renal replacement therapy.<sup><a data-tab="pane-pcw-references" href="#R2" id="R2R" class="tab-link">2</a>,<a data-tab="pane-pcw-references" href="#R3" id="R3R" class="tab-link">3</a></sup>
 Low estimated glomerular filtration rate (eGFR) or presence of 
albuminuria independently predict CV outcomes such as CV death, 
myocardial infarction (MI), and stroke in patients with T2DM.<sup><a data-tab="pane-pcw-references" href="#R4%20R5%20R6%20R7" id="R4 R5 R6 R7R" class="tab-link">4–7</a></sup>
 Current standard CV treatment for these patients broadly aligns with 
current guidelines for patients with normal kidney function. However, a 
beneficial effect shown in patients with normal kidney function does not
 necessarily apply to patients with CKD, for example, as has been seen 
with statins in patients with advanced CKD.<sup><a data-tab="pane-pcw-references" href="#R8%20R9%20R10" id="R8 R9 R10R" class="tab-link">8–10</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In previous landmark trials, intensive glycemic control limited the risk of microvascular complications of T2DM<sup><a data-tab="pane-pcw-references" href="#R11" id="R11R" class="tab-link">11</a></sup> but did not demonstrate CV benefits.<sup><a data-tab="pane-pcw-references" href="#R12" id="R12R" class="tab-link">12</a></sup> Results from recent CV outcome trials with basal insulin<sup><a data-tab="pane-pcw-references" href="#R13" id="R13R" class="tab-link">13</a>,<a data-tab="pane-pcw-references" href="#R14" id="R14R" class="tab-link">14</a></sup> and dipeptidyl peptidase-4 inhibitors<sup><a data-tab="pane-pcw-references" href="#R15%20R16%20R17" id="R15 R16 R17R" class="tab-link">15–17</a></sup> ensured CV safety, whereas CV benefits were reported for glucagon-like peptide-1 receptor agonists<sup><a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a>,<a data-tab="pane-pcw-references" href="#R19" id="R19R" class="tab-link">19</a></sup> and sodium-glucose cotransporter-2 (SGLT-2) inhibitors,<sup><a data-tab="pane-pcw-references" href="#R20" id="R20R" class="tab-link">20</a>,<a data-tab="pane-pcw-references" href="#R21" id="R21R" class="tab-link">21</a></sup> thus suggesting CV-protective effects at least partly independent of glycemic control.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">There
 are no dedicated controlled trials that have examined interventions or 
medications to lower the excessive CV risk of CKD in association with 
T2DM. Subgroup analyses of the recent CV outcome trials in T2DM with 
dipeptidyl peptidase-4 inhibitors<sup><a data-tab="pane-pcw-references" href="#R15%20R16%20R17" id="R15 R16 R17R" class="tab-link">15–17</a>,<a data-tab="pane-pcw-references" href="#R22%20R23%20R24" id="R22 R23 R24R" class="tab-link">22–24</a></sup> and SGLT-2 inhibitors<sup><a data-tab="pane-pcw-references" href="#R20" id="R20R" class="tab-link">20</a>,<a data-tab="pane-pcw-references" href="#R21" id="R21R" class="tab-link">21</a>,<a data-tab="pane-pcw-references" href="#R25" id="R25R" class="tab-link">25</a></sup>
 showed no different effects of the antihyperglycemic medications on 
major CV outcomes in those with and without CKD. Many antihyperglycemic 
medications exhibit altered pharmacokinetics and pharmacodynamics when 
kidney function is reduced,<sup><a data-tab="pane-pcw-references" href="#R26" id="R26R" class="tab-link">26</a></sup>
 which may potentially affect safety and efficacy. Furthermore, the dose
 of many of those medications needs to be reduced in the presence of 
CKD, which may affect their impact on CV disease. The metabolism and 
elimination of liraglutide is mostly unaffected with decreasing kidney 
function, and it has been approved for use in patients with severe renal
 impairment without dose adjustment.<sup><a data-tab="pane-pcw-references" href="#R27" id="R27R" class="tab-link">27</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of 
CV Outcome Results) reported a reduced risk of CV outcomes, all-cause 
death, and renal outcomes for patients with T2DM on standard of care 
treated with liraglutide compared with placebo.<sup><a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a>,<a data-tab="pane-pcw-references" href="#R28" id="R28R" class="tab-link">28</a></sup>
 As such, liraglutide is now approved to reduce the risk of major 
adverse CV events in adults with T2DM and established CV disease.<sup><a data-tab="pane-pcw-references" href="#R27" id="R27R" class="tab-link">27</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 aim of these analyses is to further examine the effect of liraglutide 
versus placebo on CV and safety outcomes in subgroups of patients with 
eGFR &lt;60 mL/min/1.73 m<sup>2</sup> versus ≥60 mL/min/1.73 m<sup>2</sup>
 and those with micro- and macroalbuminuria versus those without 
albuminuria. We hypothesized that the CV benefit would remain evident in
 those subgroups with CKD.</p>
<h3 class="article-section__title to-section " id="d3e597">Methods</h3>
<h4 class="article-section__title" id="d3e602">Design</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 data analyzed for this publication are available from the corresponding
 author on reasonable request. The trial design and methods have been 
published previously.<sup><a data-tab="pane-pcw-references" href="#R29" id="R29R" class="tab-link">29</a></sup>
 LEADER was a multicenter, double-blind, placebo-controlled trial 
performed at 410 sites in 32 countries. Patients with T2DM and a high 
risk of CV disease were randomized 1:1 to liraglutide or placebo, both 
in addition to standard of care.<sup><a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a>,<a data-tab="pane-pcw-references" href="#R29" id="R29R" class="tab-link">29</a></sup></p>
<h4 class="article-section__title" id="d3e621">Patients</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Patients with T2DM and a glycohemoglobin (HbA<sub>1c</sub>)
 level ≥7.0%, with no upper limit, were eligible if they were either 
drug-naive or treated with oral antihyperglycemic agents or insulin 
(human neutral protamine Hagedorn, long-acting analogue, or premixed 
only). LEADER was designed to recruit a subgroup of ≥660 patients with 
an eGFR &lt;60 mL/min/1.73 m<sup>2</sup>: ≈220 patients with severe renal impairment (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>) and ≥440 patients with moderate renal impairment (CKD stage 3; eGFR 30–60 mL/min/1.73 m<sup>2</sup>).<sup><a data-tab="pane-pcw-references" href="#R28" id="R28R" class="tab-link">28</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Other
 major inclusion criteria were either (1) ≥50 years of age with ≥1 CV 
comorbidity, including prior MI or stroke; prior coronary, carotid, or 
peripheral arterial revascularization or presence of &gt;50% stenosis; 
documented coronary heart disease; CKD ≥stage 3; or chronic heart 
failure New York Heart Association class II–III; or (2) ≥60 years of age
 with ≥1 more CV risk factor, including micro- or macroalbuminuria, 
hypertension and left ventricular hypertrophy, left ventricular systolic
 or diastolic dysfunction, or an ankle-brachial index &lt;0.9. Complete 
inclusion and exclusion criteria were published in the original trial 
report.<sup><a data-tab="pane-pcw-references" href="#R29" id="R29R" class="tab-link">29</a></sup></p>
<h4 class="article-section__title" id="d3e651">CKD Subgroups</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">CKD subgroups in these analyses were prespecified based on baseline eGFR (&lt;60 and ≥60 mL/min/1.73 m<sup>2</sup>)
 and baseline albuminuria (without albuminuria and micro- and 
macroalbuminuria [&lt;30 mg/g versus ≥30 mg/g creatinine]) measured at 
randomization. In addition to the main comparisons between baseline eGFR
 subgroups and baseline albuminuria subgroups, a comparison for the 
primary composite CV outcome and expanded composite CV outcome was 
conducted between a subgroup of patients of particular high renal risk, 
namely, with both low eGFR and micro- and macroalbuminuria versus a 
subgroup of patients who had ≥1 of an eGFR ≥60 mL/min/1.73 m<sup>2</sup> or normoalbuminuria. We also analyzed eGFR as a continuous variable using a restricted cubic splines model.</p>
<h4 class="article-section__title" id="d3e666">Study Procedures</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">After
 a 2-week placebo run-in to establish injection adherence, patients were
 randomized in a blinded manner 1:1 to 1.8 mg (or maximum tolerated 
dose) of liraglutide or matching placebo once daily, in addition to 
standard of care. For patients with suboptimal glucose control after 
randomization, dose increase or initiation of any antihyperglycemic 
agents (except glucagon-like peptide-1 receptor agonists, dipeptidyl 
peptidase-4 inhibitors, or pramlintide) was permitted, and investigators
 were directed to treat all patients to standard of care according to 
guidelines.<sup><a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a></sup></p>
<h4 class="article-section__title" id="d3e679">Outcomes</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 primary outcome was the time from randomization to first occurrence of a
 composite CV outcome consisting of CV death, nonfatal (including 
silent) MI, or nonfatal stroke. Secondary time-to-event outcomes 
included an expanded composite CV outcome (CV death, nonfatal MI, 
nonfatal stroke, coronary revascularization, or hospitalization for 
unstable angina pectoris or heart failure), CV death, all strokes (fatal
 and nonfatal), all MIs (fatal and nonfatal), and all-cause death. Other
 secondary outcomes included change in HbA<sub>1c</sub>, body weight, 
blood pressure, and low-density lipoprotein cholesterol from baseline to
 36 months. CV events were adjudicated in a blinded manner by 
board-certified cardiologist experts via an external contract research 
organization (ICON). Serious adverse events and predefined medical 
events of special interest (MESIs) were reported by the investigators or
 captured via prespecified searches among all adverse events and 
laboratory results. A MESI was a predefined event of scientific and 
medical concern, which can be serious or nonserious, and not necessarily
 with a causal relationship with the trial product.<sup><a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a></sup></p>
<h4 class="article-section__title" id="d3e694">Statistical Analysis</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The statistical analysis plan for LEADER has been published previously.<sup><a data-tab="pane-pcw-references" href="#R28" id="R28R" class="tab-link">28</a>,<a data-tab="pane-pcw-references" href="#R29" id="R29R" class="tab-link">29</a></sup>
 The required sample size was based on the primary composite CV outcome.
 All randomized patients were included and contributed to each analysis 
from the time of randomization until first occurrence of the analyzed 
outcome, death, or end of follow-up, whichever came first. Between-group
 comparisons of effectiveness and safety laboratory assessments were 
performed at 36 months, the last trial visit at which such assessments 
were made at the same time point for the entire population. All the 
analyses were performed at the nominal α level of 0.05 without 
correction for multiple hypothesis testing. Time-to-event analyses 
applied a Cox proportional hazards model with treatment as a covariate. 
For each outcome, the interaction between treatment group and CKD 
subgroup was evaluated in a model adjusting for baseline covariates, 
including sex, region, age, diabetes mellitus duration, race, ethnicity,
 CV risk (established disease versus risk factors only), 
antihyperglycemic therapy, body mass index, and HbA<sub>1c</sub>. An 
additional analysis of the primary outcome considered continuous eGFR as
 a restricted cubic spline function, and a test of interaction between 
this term and treatment group was performed.</p>
<h4 class="article-section__title" id="d3e713">Ethics</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 trial was approved by institutional review boards, and all patients 
provided written informed consent. The trial was conducted in accordance
 with the Declaration of Helsinki.</p>
<h3 class="article-section__title to-section " id="d3e723">Results</h3>
<h4 class="article-section__title" id="d3e728">Patients</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The disposition of trial participants has been published previously.<sup><a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a></sup> Patient characteristics and demographics at baseline by eGFR and albuminuria status are shown in <a class="ref showTableEvent" data-id="T1" href="#T1">Table 1</a>. Mean eGFR in patients with baseline eGFR &lt;60 and ≥60 mL/min/1.73 m<sup>2</sup> (n=2158 and n=7182, respectively) was 45.7±10.9 and 90.8±21.6 mL/min/1.73 m<sup>2</sup>, respectively, with no differences between treatment groups (<a class="ref showTableEvent" data-id="T1" href="#T1">Table 1</a>). Those with eGFR &lt;60 mL/min/1.73 m<sup>2</sup>
 generally had a slightly higher usage of antihypertensive, diuretic, 
and lipid-lowering medications as well as higher prior insulin use 
compared with those with eGFR ≥60 mL/min/1.73 m<sup>2</sup> (<a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.036418">Table I in the online-only Data Supplement</a>).</p>
<div class="article-table-content" id="T1">
<table class="table article-section__table">
<caption><strong><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns"><strong class="captionLabel">Table 1.</strong> Patient Baseline Characteristics and Demographics by eGFR and Albuminuria Status</p></strong></caption>
<thead xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">
<tr>
<th colspan="1" rowspan="2" align="left">Parameter</th>
<th colspan="2" rowspan="1" align="center">eGFR &lt;60 mL/min/1.73 m<sup>2</sup>
</th>
<th colspan="2" rowspan="1" align="center">eGFR ≥60 mL/min/1.73 m<sup>2</sup>
</th>
<th colspan="2" rowspan="1" align="center">Micro/Macroalbuminuria</th>
<th colspan="2" rowspan="1" align="center">Normoalbuminuria</th>
</tr>
<tr>
<th colspan="1" rowspan="1" align="center">Liraglutide</th>
<th colspan="1" rowspan="1" align="center">Placebo</th>
<th colspan="1" rowspan="1" align="center">Liraglutide</th>
<th colspan="1" rowspan="1" align="center">Placebo</th>
<th colspan="1" rowspan="1" align="center">Liraglutide</th>
<th colspan="1" rowspan="1" align="center">Placebo</th>
<th colspan="1" rowspan="1" align="center">Liraglutide</th>
<th colspan="1" rowspan="1" align="center">Placebo</th>
</tr>
</thead>
<tbody xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">
<tr>
<td colspan="1" rowspan="1" align="left">N</td>
<td colspan="1" rowspan="1" align="center">1116</td>
<td colspan="1" rowspan="1" align="center">1042</td>
<td colspan="1" rowspan="1" align="center">3552</td>
<td colspan="1" rowspan="1" align="center">3630</td>
<td colspan="1" rowspan="1" align="center">1684</td>
<td colspan="1" rowspan="1" align="center">1738</td>
<td colspan="1" rowspan="1" align="center">2894</td>
<td colspan="1" rowspan="1" align="center">2821</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Age, y (SD)</td>
<td colspan="1" rowspan="1" align="center">67.3 (7.5)</td>
<td colspan="1" rowspan="1" align="center">67.3 (7.5)</td>
<td colspan="1" rowspan="1" align="center">63.2 (6.9)</td>
<td colspan="1" rowspan="1" align="center">63.5 (6.9)</td>
<td colspan="1" rowspan="1" align="center">64.5 (7.2)</td>
<td colspan="1" rowspan="1" align="center">64.9 (7.2)</td>
<td colspan="1" rowspan="1" align="center">64.0 (7.2)</td>
<td colspan="1" rowspan="1" align="center">64.1 (7.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Male sex, %</td>
<td colspan="1" rowspan="1" align="center">61.9</td>
<td colspan="1" rowspan="1" align="center">60.6</td>
<td colspan="1" rowspan="1" align="center">65.3</td>
<td colspan="1" rowspan="1" align="center">65.0</td>
<td colspan="1" rowspan="1" align="center">68.3</td>
<td colspan="1" rowspan="1" align="center">67.7</td>
<td colspan="1" rowspan="1" align="center">62.5</td>
<td colspan="1" rowspan="1" align="center">61.7</td>
</tr>
<tr><td colspan="9" rowspan="1" align="left">Region, N (%)</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Europe</td>
<td colspan="1" rowspan="1" align="center">332 (29.7)</td>
<td colspan="1" rowspan="1" align="center">326 (31.3)</td>
<td colspan="1" rowspan="1" align="center">1307 (36.8)</td>
<td colspan="1" rowspan="1" align="center">1331 (36.7)</td>
<td colspan="1" rowspan="1" align="center">536 (31.8)</td>
<td colspan="1" rowspan="1" align="center">533 (30.7)</td>
<td colspan="1" rowspan="1" align="center">1066 (36.8)</td>
<td colspan="1" rowspan="1" align="center">1092 (38.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> North America</td>
<td colspan="1" rowspan="1" align="center">404 (36.2)</td>
<td colspan="1" rowspan="1" align="center">387 (37.1)</td>
<td colspan="1" rowspan="1" align="center">997 (28.1)</td>
<td colspan="1" rowspan="1" align="center">1059 (29.2)</td>
<td colspan="1" rowspan="1" align="center">512 (30.4)</td>
<td colspan="1" rowspan="1" align="center">571 (32.9)</td>
<td colspan="1" rowspan="1" align="center">864 (29.9)</td>
<td colspan="1" rowspan="1" align="center">832 (29.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Asia</td>
<td colspan="1" rowspan="1" align="center">109 (9.8)</td>
<td colspan="1" rowspan="1" align="center">69 (6.6)</td>
<td colspan="1" rowspan="1" align="center">251 (7.1)</td>
<td colspan="1" rowspan="1" align="center">282 (7.8)</td>
<td colspan="1" rowspan="1" align="center">176 (10.5)</td>
<td colspan="1" rowspan="1" align="center">162 (9.3)</td>
<td colspan="1" rowspan="1" align="center">182 (6.3)</td>
<td colspan="1" rowspan="1" align="center">186 (6.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Rest of the world</td>
<td colspan="1" rowspan="1" align="center">271 (24.3)</td>
<td colspan="1" rowspan="1" align="center">260 (25.0)</td>
<td colspan="1" rowspan="1" align="center">997 (28.1)</td>
<td colspan="1" rowspan="1" align="center">958 (26.4)</td>
<td colspan="1" rowspan="1" align="center">460 (27.3)</td>
<td colspan="1" rowspan="1" align="center">472 (27.2)</td>
<td colspan="1" rowspan="1" align="center">782 (27.0)</td>
<td colspan="1" rowspan="1" align="center">711 (25.2)</td>
</tr>
<tr><td colspan="9" rowspan="1" align="left">Race, N (%)</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> White</td>
<td colspan="1" rowspan="1" align="center">847 (75.9)</td>
<td colspan="1" rowspan="1" align="center">786 (75.4)</td>
<td colspan="1" rowspan="1" align="center">2769 (78.0)</td>
<td colspan="1" rowspan="1" align="center">2836 (78.1)</td>
<td colspan="1" rowspan="1" align="center">1242 (73.8)</td>
<td colspan="1" rowspan="1" align="center">1269 (73.0)</td>
<td colspan="1" rowspan="1" align="center">2306 (79.7)</td>
<td colspan="1" rowspan="1" align="center">2266 (80.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Black</td>
<td colspan="1" rowspan="1" align="center">77 (6.9)</td>
<td colspan="1" rowspan="1" align="center">107 (10.3)</td>
<td colspan="1" rowspan="1" align="center">293 (8.2)</td>
<td colspan="1" rowspan="1" align="center">300 (8.3)</td>
<td colspan="1" rowspan="1" align="center">142 (8.4)</td>
<td colspan="1" rowspan="1" align="center">181 (10.4)</td>
<td colspan="1" rowspan="1" align="center">219 (7.6)</td>
<td colspan="1" rowspan="1" align="center">218 (7.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Asian</td>
<td colspan="1" rowspan="1" align="center">135 (12.1)</td>
<td colspan="1" rowspan="1" align="center">96 (9.2)</td>
<td colspan="1" rowspan="1" align="center">336 (9.5)</td>
<td colspan="1" rowspan="1" align="center">369 (10.2)</td>
<td colspan="1" rowspan="1" align="center">223 (13.2)</td>
<td colspan="1" rowspan="1" align="center">209 (12.0)</td>
<td colspan="1" rowspan="1" align="center">244 (8.4)</td>
<td colspan="1" rowspan="1" align="center">247 (8.8)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Other</td>
<td colspan="1" rowspan="1" align="center">57 (5.1)</td>
<td colspan="1" rowspan="1" align="center">53 (5.1)</td>
<td colspan="1" rowspan="1" align="center">154 (4.3)</td>
<td colspan="1" rowspan="1" align="center">125 (3.4)</td>
<td colspan="1" rowspan="1" align="center">77 (4.6)</td>
<td colspan="1" rowspan="1" align="center">79 (4.5)</td>
<td colspan="1" rowspan="1" align="center">125 (4.3)</td>
<td colspan="1" rowspan="1" align="center">90 (3.2)</td>
</tr>
<tr><td colspan="9" rowspan="1" align="left">Smoking, N (%)</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Current</td>
<td colspan="1" rowspan="1" align="center">92 (8.2)</td>
<td colspan="1" rowspan="1" align="center">88 (8.4)</td>
<td colspan="1" rowspan="1" align="center">475 (13.4)</td>
<td colspan="1" rowspan="1" align="center">475 (13.1)</td>
<td colspan="1" rowspan="1" align="center">215 (12.8)</td>
<td colspan="1" rowspan="1" align="center">253 (14.6)</td>
<td colspan="1" rowspan="1" align="center">339 (11.7)</td>
<td colspan="1" rowspan="1" align="center">297 (10.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Previous</td>
<td colspan="1" rowspan="1" align="center">492 (44.1)</td>
<td colspan="1" rowspan="1" align="center">501 (48.1)</td>
<td colspan="1" rowspan="1" align="center">1659 (46.7)</td>
<td colspan="1" rowspan="1" align="center">1688 (46.5)</td>
<td colspan="1" rowspan="1" align="center">788 (46.8)</td>
<td colspan="1" rowspan="1" align="center">825 (47.5)</td>
<td colspan="1" rowspan="1" align="center">1330 (46.0)</td>
<td colspan="1" rowspan="1" align="center">1306 (46.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Never</td>
<td colspan="1" rowspan="1" align="center">532 (47.7)</td>
<td colspan="1" rowspan="1" align="center">453 (43.5)</td>
<td colspan="1" rowspan="1" align="center">1418 (39.9)</td>
<td colspan="1" rowspan="1" align="center">1467 (40.4)</td>
<td colspan="1" rowspan="1" align="center">681 (40.4)</td>
<td colspan="1" rowspan="1" align="center">660 (38.0)</td>
<td colspan="1" rowspan="1" align="center">1225 (42.3)</td>
<td colspan="1" rowspan="1" align="center">1218 (43.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Prior stroke/MI, N (%)</td>
<td colspan="1" rowspan="1" align="center">416 (37.3)</td>
<td colspan="1" rowspan="1" align="center">387 (37.1)</td>
<td colspan="1" rowspan="1" align="center">1449 (40.8)</td>
<td colspan="1" rowspan="1" align="center">1440 (39.7)</td>
<td colspan="1" rowspan="1" align="center">649 (38.5)</td>
<td colspan="1" rowspan="1" align="center">649 (37.3)</td>
<td colspan="1" rowspan="1" align="center">1178 (40.7)</td>
<td colspan="1" rowspan="1" align="center">1136 (40.3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> History of MI, N (%)</td>
<td colspan="1" rowspan="1" align="center">325 (29.1)</td>
<td colspan="1" rowspan="1" align="center">294 (28.2)</td>
<td colspan="1" rowspan="1" align="center">1139 (32.1)</td>
<td colspan="1" rowspan="1" align="center">1106 (30.5)</td>
<td colspan="1" rowspan="1" align="center">506 (30.0)</td>
<td colspan="1" rowspan="1" align="center">500 (28.8)</td>
<td colspan="1" rowspan="1" align="center">935 (32.3)</td>
<td colspan="1" rowspan="1" align="center">866 (30.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> History of stroke, N (%)</td>
<td colspan="1" rowspan="1" align="center">138 (12.4)</td>
<td colspan="1" rowspan="1" align="center">127 (12.2)</td>
<td colspan="1" rowspan="1" align="center">408 (11.5)</td>
<td colspan="1" rowspan="1" align="center">430 (11.8)</td>
<td colspan="1" rowspan="1" align="center">193 (11.5)</td>
<td colspan="1" rowspan="1" align="center">202 (11.6)</td>
<td colspan="1" rowspan="1" align="center">336 (11.6)</td>
<td colspan="1" rowspan="1" align="center">341 (12.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Diabetes mellitus duration, y (SD)</td>
<td colspan="1" rowspan="1" align="center">15.4 (8.7)</td>
<td colspan="1" rowspan="1" align="center">14.9 (8.5)</td>
<td colspan="1" rowspan="1" align="center">12.0 (7.5)</td>
<td colspan="1" rowspan="1" align="center">12.3 (7.8)</td>
<td colspan="1" rowspan="1" align="center">14.2 (8.1)</td>
<td colspan="1" rowspan="1" align="center">14.3 (8.3)</td>
<td colspan="1" rowspan="1" align="center">11.9 (7.7)</td>
<td colspan="1" rowspan="1" align="center">11.9 (7.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Hypertension, N (%)</td>
<td colspan="1" rowspan="1" align="center">1067 (95.6)</td>
<td colspan="1" rowspan="1" align="center">998 (95.8)</td>
<td colspan="1" rowspan="1" align="center">3194 (89.9)</td>
<td colspan="1" rowspan="1" align="center">3252 (89.6)</td>
<td colspan="1" rowspan="1" align="center">1578 (93.7)</td>
<td colspan="1" rowspan="1" align="center">1624 (93.4)</td>
<td colspan="1" rowspan="1" align="center">2603 (89.9)</td>
<td colspan="1" rowspan="1" align="center">2523 (89.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Body weight, kg (SD)</td>
<td colspan="1" rowspan="1" align="center">91.3 (21.1)</td>
<td colspan="1" rowspan="1" align="center">91.5 (21.8)</td>
<td colspan="1" rowspan="1" align="center">92.1 (21.2)</td>
<td colspan="1" rowspan="1" align="center">91.6 (20.4)</td>
<td colspan="1" rowspan="1" align="center">91.0 (22.1)</td>
<td colspan="1" rowspan="1" align="center">91.3 (21.6)</td>
<td colspan="1" rowspan="1" align="center">92.4 (20.6)</td>
<td colspan="1" rowspan="1" align="center">91.6 (20.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">BMI, kg/m<sup>2</sup> (SD)</td>
<td colspan="1" rowspan="1" align="center">32.6 (6.4)</td>
<td colspan="1" rowspan="1" align="center">32.7 (6.6)</td>
<td colspan="1" rowspan="1" align="center">32.5 (6.3)</td>
<td colspan="1" rowspan="1" align="center">32.4 (6.2)</td>
<td colspan="1" rowspan="1" align="center">32.2 (6.4)</td>
<td colspan="1" rowspan="1" align="center">32.3 (6.3)</td>
<td colspan="1" rowspan="1" align="center">32.7 (6.2)</td>
<td colspan="1" rowspan="1" align="center">32.5 (6.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">HbA<sub>1c</sub>, % (SD)</td>
<td colspan="1" rowspan="1" align="center">8.7 (1.6)</td>
<td colspan="1" rowspan="1" align="center">8.6 (1.5)</td>
<td colspan="1" rowspan="1" align="center">8.7 (1.5)</td>
<td colspan="1" rowspan="1" align="center">8.7 (1.5)</td>
<td colspan="1" rowspan="1" align="center">9.1 (1.7)</td>
<td colspan="1" rowspan="1" align="center">8.9 (1.6)</td>
<td colspan="1" rowspan="1" align="center">8.5 (1.4)</td>
<td colspan="1" rowspan="1" align="center">8.5 (1.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Creatinine, mg/dL (SD)</td>
<td colspan="1" rowspan="1" align="center">1.53 (0.64)</td>
<td colspan="1" rowspan="1" align="center">1.52 (0.58)</td>
<td colspan="1" rowspan="1" align="center">0.83 (0.18)</td>
<td colspan="1" rowspan="1" align="center">0.83 (0.18)</td>
<td colspan="1" rowspan="1" align="center">1.13 (0.61)</td>
<td colspan="1" rowspan="1" align="center">1.10 (0.56)</td>
<td colspan="1" rowspan="1" align="center">0.92 (0.32)</td>
<td colspan="1" rowspan="1" align="center">0.91 (0.29)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">eGFR, mL/min/1.73 m<sup>2</sup> (SD)</td>
<td colspan="1" rowspan="1" align="center">45.5 (10.9)</td>
<td colspan="1" rowspan="1" align="center">45.8 (10.8)</td>
<td colspan="1" rowspan="1" align="center">91.1 (21.5)</td>
<td colspan="1" rowspan="1" align="center">90.5 (21.8)</td>
<td colspan="1" rowspan="1" align="center">74.0 (29.5)</td>
<td colspan="1" rowspan="1" align="center">75.0 (28.9)</td>
<td colspan="1" rowspan="1" align="center">83.8 (25.5)</td>
<td colspan="1" rowspan="1" align="center">84.0 (25.5)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Normal (eGFR ≥90), N (%)</td>
<td colspan="1" rowspan="1" align="center">0 (0.0)</td>
<td colspan="1" rowspan="1" align="center">0 (0.0)</td>
<td colspan="1" rowspan="1" align="center">1620 (45.6)</td>
<td colspan="1" rowspan="1" align="center">1655 (45.6)</td>
<td colspan="1" rowspan="1" align="center">475 (28.2)</td>
<td colspan="1" rowspan="1" align="center">509 (29.3)</td>
<td colspan="1" rowspan="1" align="center">1112 (38.4)</td>
<td colspan="1" rowspan="1" align="center">1104 (39.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Mild impairment (eGFR 60–89), N (%)</td>
<td colspan="1" rowspan="1" align="center">0 (0.0)</td>
<td colspan="1" rowspan="1" align="center">0 (0.0)</td>
<td colspan="1" rowspan="1" align="center">1932 (54.4)</td>
<td colspan="1" rowspan="1" align="center">1975 (54.4)</td>
<td colspan="1" rowspan="1" align="center">626 (37.2)</td>
<td colspan="1" rowspan="1" align="center">682 (39.2)</td>
<td colspan="1" rowspan="1" align="center">1277 (44.1)</td>
<td colspan="1" rowspan="1" align="center">1246 (44.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Moderate impairment (eGFR 30–59), N (%)</td>
<td colspan="1" rowspan="1" align="center">999 (89.5)</td>
<td colspan="1" rowspan="1" align="center">935 (89.7)</td>
<td colspan="1" rowspan="1" align="center">0 (0.0)</td>
<td colspan="1" rowspan="1" align="center">0 (0.0)</td>
<td colspan="1" rowspan="1" align="center">498 (29.6)</td>
<td colspan="1" rowspan="1" align="center">464 (26.7)</td>
<td colspan="1" rowspan="1" align="center">477 (16.5)</td>
<td colspan="1" rowspan="1" align="center">451 (16.0)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left"> Severe impairment (eGFR &lt;30), N (%)</td>
<td colspan="1" rowspan="1" align="center">117 (10.5)</td>
<td colspan="1" rowspan="1" align="center">107 (10.3)</td>
<td colspan="1" rowspan="1" align="center">0 (0.0)</td>
<td colspan="1" rowspan="1" align="center">0 (0.0)</td>
<td colspan="1" rowspan="1" align="center">85 (5.0)</td>
<td colspan="1" rowspan="1" align="center">83 (4.8)</td>
<td colspan="1" rowspan="1" align="center">28 (1.0)</td>
<td colspan="1" rowspan="1" align="center">20 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">UACR<a class="ref showTableEvent" data-id="tab1fn2" href="#tab1fn2">*</a>, mg/g (q1; q3)</td>
<td colspan="1" rowspan="1" align="center">47.3 (7.8; 236.8)</td>
<td colspan="1" rowspan="1" align="center">51.8 (8.0; 305.9)</td>
<td colspan="1" rowspan="1" align="center">15.7 (4.4; 44.8)</td>
<td colspan="1" rowspan="1" align="center">16.5 (4.3; 48.5)</td>
<td colspan="1" rowspan="1" align="center">156.7 (53.7; 356.8)</td>
<td colspan="1" rowspan="1" align="center">162.5 (53.3; 396.7)</td>
<td colspan="1" rowspan="1" align="center">6.2 (3.1; 13.2)</td>
<td colspan="1" rowspan="1" align="center">6.1 (3.0; 13.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">Total cholesterol, mmol/L (SD)</td>
<td colspan="1" rowspan="1" align="center">4.4 (1.2)</td>
<td colspan="1" rowspan="1" align="center">4.4 (1.2)</td>
<td colspan="1" rowspan="1" align="center">4.4 (1.2)</td>
<td colspan="1" rowspan="1" align="center">4.4 (1.2)</td>
<td colspan="1" rowspan="1" align="center">4.5 (1.2)</td>
<td colspan="1" rowspan="1" align="center">4.5 (1.3)</td>
<td colspan="1" rowspan="1" align="center">4.4 (1.1)</td>
<td colspan="1" rowspan="1" align="center">4.4 (1.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">LDL-C, mmol/L (SD)</td>
<td colspan="1" rowspan="1" align="center">2.3 (1.0)</td>
<td colspan="1" rowspan="1" align="center">2.3 (0.9)</td>
<td colspan="1" rowspan="1" align="center">2.3 (0.9)</td>
<td colspan="1" rowspan="1" align="center">2.3 (0.9)</td>
<td colspan="1" rowspan="1" align="center">2.4 (1.0)</td>
<td colspan="1" rowspan="1" align="center">2.4 (1.0)</td>
<td colspan="1" rowspan="1" align="center">2.3 (0.9)</td>
<td colspan="1" rowspan="1" align="center">2.3 (0.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">SBP, mm Hg (SD)</td>
<td colspan="1" rowspan="1" align="center">136.0 (19.5)</td>
<td colspan="1" rowspan="1" align="center">136.8 (19.5)</td>
<td colspan="1" rowspan="1" align="center">135.9 (17.2)</td>
<td colspan="1" rowspan="1" align="center">135.7 (17.1)</td>
<td colspan="1" rowspan="1" align="center">140.6 (18.7)</td>
<td colspan="1" rowspan="1" align="center">139.9 (19.2)</td>
<td colspan="1" rowspan="1" align="center">133.2 (16.6)</td>
<td colspan="1" rowspan="1" align="center">133.5 (16.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">DBP, mm Hg (SD)</td>
<td colspan="1" rowspan="1" align="center">74.7 (10.5)</td>
<td colspan="1" rowspan="1" align="center">75.5 (10.6)</td>
<td colspan="1" rowspan="1" align="center">78.0 (10.1)</td>
<td colspan="1" rowspan="1" align="center">77.4 (10.0)</td>
<td colspan="1" rowspan="1" align="center">78.5 (10.6)</td>
<td colspan="1" rowspan="1" align="center">77.7 (10.7)</td>
<td colspan="1" rowspan="1" align="center">76.5 (10.1)</td>
<td colspan="1" rowspan="1" align="center">76.6 (9.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">HR, bpm (SD)</td>
<td colspan="1" rowspan="1" align="center">71.6 (11.6)</td>
<td colspan="1" rowspan="1" align="center">71.7 (11.8)</td>
<td colspan="1" rowspan="1" align="center">73.0 (11.2)</td>
<td colspan="1" rowspan="1" align="center">72.8 (11.3)</td>
<td colspan="1" rowspan="1" align="center">73.2 (11.5)</td>
<td colspan="1" rowspan="1" align="center">73.0 (11.7)</td>
<td colspan="1" rowspan="1" align="center">72.3 (11.2)</td>
<td colspan="1" rowspan="1" align="center">72.3 (11.2)</td>
</tr>
</tbody>
</table>
<div class="tableFooter">
<div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="footnote"><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">BMI
 indicates body mass index; bpm, beats per minute; DBP, diastolic blood 
pressure; eGFR, estimated glomerular filtration rate; HbA<sub>1c</sub>, 
glycohemoglobin; HR, heart rate; LDL-C, low-density lipoprotein 
cholesterol; MI, myocardial infarction; SBP, systolic blood pressure; 
and UACR, urine albumin-to-creatinine ratio.</p></div>
<div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="footnote" id="tab1fn2"><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">*UACR
 is geometric mean (q1; q3). Normoalbuminuria and micro/macroalbuminuria
 defined as &lt;30 and ≥30 mg/g creatinine, respectively.</p></div>
</div>
</div>
<h4 class="article-section__title" id="d3e1935">Primary Composite CV Outcome: Time to First Major Adverse CV Events</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 primary composite CV outcome (1302 events in total) occurred in a lower
 proportion of patients taking liraglutide than placebo (15.4% versus 
21.4%, respectively, in those with eGFR &lt;60 mL/min/1.73 m<sup>2</sup>, and 12.3% versus 13.0%, respectively, in those with eGFR ≥60 mL/min/1.73 m<sup>2</sup>).
 For the primary composite CV outcome, the risk reduction observed with 
liraglutide was greater in the subgroup of patients with eGFR &lt;60 
mL/min/1.73 m<sup>2</sup> (hazard ratio [HR], 0.69; 95% CI, 0.57–0.85) than in those with eGFR ≥60 mL/min/1.73 m<sup>2</sup> (HR, 0.94; 95% CI, 0.83–1.07; interaction <i>P</i>=0.01) (<a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figure 1</a>). However, examining treatment differences in finer eGFR subgroups of 15 mL/min/1.73 m<sup>2</sup>
 intervals revealed no consistent difference in the treatment effect of 
liraglutide on the primary composite CV outcome dependent on eGFR 
(interaction <i>P</i>=0.13) (<a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">Figure 2</a>). There was also no interaction of eGFR at baseline with the treatment effect when eGFR was used as a continuous variable (<a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.036418">Figure I in the online-only Data Supplement</a>). Irrespective of treatment, the primary composite CV outcome was more likely in patients with eGFR &lt;60 mL/min/1.73 m<sup>2</sup> compared with eGFR ≥60 mL/min/1.73 m<sup>2</sup> (<i>P</i>&lt;0.0001).</p>
<figure id="F1" class="article__inlineFigure"><img class="figure__image" src="2908fig01.gif" alt="Figure 1."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/a76243ac-31f7-4669-a806-68ce1c08873f/2908fig01.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F1&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 1.</strong> <strong>Hazard ratios between treatment groups for primary and key secondary outcomes by baseline eGFR and albuminuria groups.</strong>
 Time-to-event analyses applied a Cox proportional-hazards model with 
treatment as a covariate. Primary composite CV outcome was a composite 
of nonfatal stroke, nonfatal MI, or CV death. The expanded composite CV 
outcome was the same as the primary composite CV outcome plus coronary 
revascularization or hospitalization for unstable AP or heart failure. 
AP indicates angina pectoris; CV, cardiovascular; eGFR, estimated 
glomerular filtration rate; MI, myocardial infarction; N, number of 
patients with an event; and %, proportion of patients with an event.</p></span></figcaption></figure><figure id="F2" class="article__inlineFigure"><img class="figure__image" src="2908fig02.gif" alt="Figure 2."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/06cf5e61-26d7-443a-ad86-4ee222c65f65/2908fig02.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F2&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 2.</strong> <strong>Hazard ratios between treatment groups for the primary composite CV outcome by baseline eGFR subgroups in all patients.</strong>
 Time to first event is analyzed using Cox proportional hazards model 
with treatment, subgroup, and the interaction between treatment and 
subgroup as factors. *<i>P</i> value is from the test statistic for 
testing the interaction between treatment and baseline eGFR-MDRD group. 
The primary composite CV outcome includes CV death, nonfatal myocardial 
infarction, or nonfatal stroke. CV indicates cardiovascular; eGFR, 
estimated glomerular filtration rate; MDRD, Modification of Diet in 
Renal Disease; and N (%), number of patients with an event (proportion 
of patients within the subgroup with an event).</p></span></figcaption></figure><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">For
 micro- and macroalbuminuria and normoalbuminuria subgroups, the 
corresponding HRs for primary and key secondary outcomes by baseline 
eGFR and time to primary composite CV outcome in patients according to 
baseline eGFR were 0.83 (95% CI, 0.71–0.97) and 0.92 (95% CI, 0.79–1.07;
 interaction <i>P</i>=0.36), respectively (<a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figure 1</a>).
 Further analyses illustrating the effect of liraglutide versus placebo 
in finer subgroups of eGFR and albuminuria and the time course for 
development of CV events can be found in <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.036418">Figures II through VI in the online-only Data Supplement</a>. A sensitivity analysis of the primary composite CV outcome, taking into account adjustment for baseline HbA<sub>1c</sub>,
 body weight, systolic blood pressure, and renin-angiotensin system 
inhibitors, revealed similar results to the unadjusted results presented
 in this study (data not shown).</p>
<h4 class="article-section__title" id="d3e2029">Individual Components of the Primary Composite CV Outcome</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 effects of liraglutide versus placebo were consistent across the 
individual components of the primary CV outcome. In the subgroup of 
patients with eGFR &lt;60 mL/min/1.73 m<sup>2</sup>, liraglutide reduced
 the risk of nonfatal MI compared with placebo (HR, 0.74; 95% CI, 
0.55–0.99) compared with those with eGFR ≥60 mL/min/1.73 m<sup>2</sup> (HR, 0.93; 95% CI, 0.77–1.13; interaction <i>P</i>=0.19) (<a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figure 1</a>). A similar pattern was observed for nonfatal stroke (HR, 0.51; 95% CI, 0.33–0.80 and HR, 1.07; 95% CI, 0.84–1.37; interaction <i>P</i>=0.004) and CV death (HR, 0.67; 95% CI, 0.50–0.90 and HR, 0.84; 95% CI, 0.67–1.05; interaction <i>P</i>=0.24) for patients with eGFR &lt;60 mL/min/1.73 m<sup>2</sup> and ≥60 mL/min/1.73 m<sup>2</sup>, respectively (<a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figure 1</a>).
 The risk of nonfatal MI, nonfatal stroke, and CV death was reduced with
 liraglutide compared with placebo in both the micro- and 
macroalbuminuria and normoalbuminuria subgroups (<a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figure 1</a>).</p>
<h4 class="article-section__title" id="d3e2069">Other Secondary Outcomes</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">All-cause
 death occurred less frequently with liraglutide versus placebo, and 
that difference was numerically greater in those with eGFR &lt;60 mL/min
 (12.9% versus 17.1%; HR, 0.74; 95% CI, 0.60–0.92) than in those with 
eGFR &gt;60 mL/min (6.7% versus 7.4%; HR, 0.90; 95% CI, 0.75–1.07; 
interaction <i>P</i>=0.19). Similarly, a greater benefit of liraglutide in those with low eGFR (<a data-tab="pane-pcw-Figures" href="#F1" id="F1R" class="">Figure 1</a>) was observed, particularly for the expanded composite CV outcome (interaction <i>P</i>=0.02), for all strokes (interaction <i>P</i>=0.01), and for all MIs (interaction <i>P</i>=0.24).</p>
<h4 class="article-section__title" id="d3e2094">Subgroups of Patients With Low eGFR and Micro- and Macroalbuminuria</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In the high-renal-risk subgroup of patients with eGFR &lt;60 mL/min/1.73 m<sup>2</sup>
 and micro- and macroalbuminuria (n=1130), liraglutide reduced the risk 
of the primary composite CV outcome compared with placebo (HR, 0.63; 95%
 CI, 0.49–0.82); a more modest risk reduction was seen for those with 
either eGFR ≥60 mL/min/1.73 m<sup>2</sup> or normoalbuminuria (n=8007) (HR, 0.93; 95% CI, 0.82–1.05; interaction <i>P</i>=0.008).</p>
<h4 class="article-section__title" id="d3e2112">Clinical Parameters</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Declines in HbA<sub>1c</sub>
 and body weight were consistently greater with liraglutide versus 
placebo for all eGFR and albuminuria subgroups. There was evidence of 
interaction between treatment and baseline eGFR for body weight 
(interaction <i>P</i>=0.01), with greater weight loss associated with liraglutide treatment among patients with eGFR &lt;60 mL/min/1.73 m<sup>2</sup>
 (estimated treatment difference, −2.92 kg; 95% CI, −3.51 to −2.33 
compared with −2.07 kg; 95% CI, −2.38 to −1.76 for those with eGFR ≥60 
mL/min/1.73 m<sup>2</sup>). Systolic blood pressure and low-density 
lipoprotein cholesterol changes were slight and varied according to 
baseline eGFR and albuminuria status. Patients with eGFR ≥60 mL/min/1.73
 m<sup>2</sup> achieved numerically greater reductions in systolic blood pressure than those with eGFR &lt;60 mL/min/1.73 m<sup>2</sup> (interaction <i>P</i>=0.12) (<a data-tab="pane-pcw-Figures" href="#F3" id="F3R" class="">Figure 3</a>).</p>
<figure id="F3" class="article__inlineFigure"><img class="figure__image" src="2908fig03.gif" alt="Figure 3."><div class="figure-links"><ul class="rlist--inline">
<li><a href="https://www.ahajournals.org/cms/attachment/d85f4a6e-53c5-41de-b1d0-341be9b1d1a2/2908fig03.gif" download="">Download figure</a></li>
<li><a href="https://www.ahajournals.org/action/downloadFigures?id=F3&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418" class="ppt-figure-link">Download PowerPoint</a></li>
</ul></div>
<figcaption><strong class="figure__title"></strong><span class="figure__caption"><p><strong class="captionLabel">Figure 3.</strong> <strong>Change in HbA1c (A), body weight (B), SBP (C), and LDL cholesterol (D) at 36 months.</strong> Interaction <i>P</i> between treatment and eGFR/albuminuria status at baseline was not significant, except for eGFR and weight (<i>P</i>=0.012).
 Changes are presented at 36 months (the last visit when all 
participants had their annual analysis of all laboratory results). eGFR 
indicates estimated glomerular filtration rate; ETD, estimated treatment
 difference; HbA<sub xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">1c</sub>,
 glycohemoglobin; LDL, low-density lipoprotein; Micro/macro, 
microalbuminuria/macroalbuminuria; Normo, normalbuminuria; and SBP, 
systolic blood pressure.</p></span></figcaption></figure><h4 class="article-section__title" id="d3e2168">Adverse Events</h4>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">As
 expected, serious adverse events, MESIs, and severe hypoglycemia were 
more common among patients with eGFR &lt;60 mL/min/1.73 m<sup>2</sup> compared with ≥60 mL/min/1.73 m<sup>2</sup>.
 In general, however, the proportion of patients with serious adverse 
events and MESIs was not increased with liraglutide treatment compared 
with placebo, although fewer MESIs were reported with placebo compared 
with liraglutide among those with eGFR ≥60 mL/min/1.73 m<sup>2</sup> and
 among patients with normoalbuminuria. Severe hypoglycemia was more 
frequent with placebo compared with liraglutide in those with eGFR 
&lt;60 mL/min/1.73 m<sup>2</sup> than ≥60 mL/min/1.73 m<sup>2</sup> (HR,
 0.63; 95% CI, 0.43–0.91 versus HR, 0.81; 95% CI, 0.59–1.12), and the 
relative benefit of liraglutide over placebo (less hypoglycemia with 
liraglutide) was greater in the eGFR &lt;60 mL/min/1.73 m<sup>2</sup> subgroup (<a class="ref showTableEvent" data-id="T2" href="#T2">Table 2</a>).</p>
<div class="article-table-content" id="T2">
<table class="table article-section__table">
<caption><strong><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns"><strong class="captionLabel">Table 2.</strong> Safety of Liraglutide by eGFR and Albuminuria Status</p></strong></caption>
<thead xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">
<tr>
<th colspan="1" rowspan="1" align="left">Variable</th>
<th colspan="1" rowspan="1" align="center">Treatment</th>
<th colspan="1" rowspan="1" align="center">N</th>
<th colspan="1" rowspan="1" align="center">%</th>
<th colspan="1" rowspan="1" align="center">HR [95% CI]</th>
</tr>
<tr><th colspan="5" rowspan="1" align="left">SAEs</th></tr>
<tr><th colspan="5" rowspan="1" align="left"> According to baseline eGFR status</th></tr>
</thead>
<tbody xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">
<tr>
<td colspan="1" rowspan="1" align="left">  eGFR &lt;60 mL/min/1.73 m<sup>2</sup>
</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">653/1116<break></break>648/1042</td>
<td colspan="1" rowspan="1" align="left">58.5<break></break>62.2</td>
<td colspan="1" rowspan="1" align="center">0.90 [0.81–1.01]</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">  eGFR ≥60 mL/min/1.73 m<sup>2</sup>
</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">1667/3552<break></break>1706/3630</td>
<td colspan="1" rowspan="1" align="left">46.9<break></break>47.0</td>
<td colspan="1" rowspan="1" align="center">1.00 [0.94–1.07]</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">  Interaction <i>P</i> between treatment and eGFR = 0.11</td></tr>
<tr><td colspan="5" rowspan="1" align="left"> According to baseline albuminuria status</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left">  Micro/macroalbuminuria</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">945/1684<break></break>1016/1738</td>
<td colspan="1" rowspan="1" align="left">56.1<break></break>58.5</td>
<td colspan="1" rowspan="1" align="center">0.93 [0.85–1.02]</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">  Normoalbuminuria</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">1334/2894<break></break>1287/2821</td>
<td colspan="1" rowspan="1" align="left">46.1<break></break>45.6</td>
<td colspan="1" rowspan="1" align="center">1.02 [0.95–1.11]</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">  Interaction <i>P</i> between treatment and albuminuria status=0.11</td></tr>
<tr><td colspan="5" rowspan="1" align="left">MESI</td></tr>
<tr><td colspan="5" rowspan="1" align="left"> According to baseline eGFR status</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left">  eGFR &lt;60 mL/min/1.73 m<sup>2</sup>
</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">680/1116<break></break>651/1042</td>
<td colspan="1" rowspan="1" align="left">60.9<break></break>62.5</td>
<td colspan="1" rowspan="1" align="center">0.98 [0.88; 1.09]</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">  eGFR ≥60 mL/min/1.73 m<sup>2</sup>
</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">1698/3552<break></break>1662/3630</td>
<td colspan="1" rowspan="1" align="left">47.8<break></break>45.8</td>
<td colspan="1" rowspan="1" align="center">1.10 [1.03; 1.18]</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">  Interaction <i>P</i> between treatment and eGFR = 0.07</td></tr>
<tr><td colspan="5" rowspan="1" align="left"> According to baseline albuminuria status</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left">  Micro/macroalbuminuria</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">962/1684<break></break>1026/1738</td>
<td colspan="1" rowspan="1" align="left">57.1<break></break>59.0</td>
<td colspan="1" rowspan="1" align="center">0.98 [0.90; 1.07]</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">  Normoalbuminuria</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">1371/2894<break></break>1230/2821</td>
<td colspan="1" rowspan="1" align="left">47.4<break></break>43.6</td>
<td colspan="1" rowspan="1" align="center">1.16 [1.08; 1.26]</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">  Interaction <i>P</i> between treatment and albuminuria status=0.004</td></tr>
<tr><td colspan="5" rowspan="1" align="left">Severe hypoglycemia</td></tr>
<tr><td colspan="5" rowspan="1" align="left"> According to baseline eGFR status</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left">  eGFR &lt;60 mL/min/1.73 m<sup>2</sup>
</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">48/1116<break></break>70/1042</td>
<td colspan="1" rowspan="1" align="left">4.3<break></break>6.7</td>
<td colspan="1" rowspan="1" align="center">0.63 [0.43; 0.91]</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">  eGFR ≥60 mL/min/1.73 m<sup>2</sup>
</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">66/3552<break></break>83/3630</td>
<td colspan="1" rowspan="1" align="left">1.9<break></break>2.3</td>
<td colspan="1" rowspan="1" align="center">0.81 [0.59; 1.12]</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">  Interaction <i>P</i> between treatment and eGFR = 0.30</td></tr>
<tr><td colspan="5" rowspan="1" align="left"> According to baseline albuminuria status</td></tr>
<tr>
<td colspan="1" rowspan="1" align="left">  Micro/macroalbuminuria</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">48/1684<break></break>85/1738</td>
<td colspan="1" rowspan="1" align="left">2.9<break></break>4.9</td>
<td colspan="1" rowspan="1" align="center">0.57 [0.40; 0.82]</td>
</tr>
<tr>
<td colspan="1" rowspan="1" align="left">  Normoalbuminuria</td>
<td colspan="1" rowspan="1" align="left">Liraglutide<break></break>Placebo</td>
<td colspan="1" rowspan="1" align="left">64/2894<break></break>63/2821</td>
<td colspan="1" rowspan="1" align="left">2.2<break></break>2.2</td>
<td colspan="1" rowspan="1" align="center">0.99 [0.70; 1.40]</td>
</tr>
<tr><td colspan="5" rowspan="1" align="left">  Interaction <i>P</i> between treatment and albuminuria status=0.03</td></tr>
</tbody>
</table>
<div class="tableFooter"><div xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="footnote"><p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Time-to-event
 analyses applied a Cox proportional hazards model with treatment as a 
covariate. eGFR indicates estimated glomerular filtration rate; HR, 
hazard ratio (liraglutide versus placebo unless otherwise stated); MESI,
 medical event of special interest; N, number of patients with an event;
 and SAE, serious adverse event; and %, proportion of patients with an 
event.</p></div></div>
</div>
<h3 class="article-section__title to-section " id="d3e2653">Discussion</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">These
 analyses demonstrate that, in subgroups of patients with T2D, high CV 
risk, and CKD, including those with low eGFR and/or elevated 
albuminuria, liraglutide reduced the risk of major adverse CV events at 
least as effectively as in subgroups without such risks. These findings 
are important given that evidence consistently shows that patients with 
diabetes and low eGFR or elevated albuminuria experience substantially 
greater CV morbidity and mortality than those with diabetes mellitus and
 normal eGFR and albuminuria.<sup><a data-tab="pane-pcw-references" href="#R5%20R6%20R7" id="R5 R6 R7R" class="tab-link">5–7</a>,<a data-tab="pane-pcw-references" href="#R30" id="R30R" class="tab-link">30</a>,<a data-tab="pane-pcw-references" href="#R31" id="R31R" class="tab-link">31</a></sup> In addition, the armamentarium of antihyperglycemic medications is restricted in those with CKD.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 benefit of liraglutide in LEADER participants with CKD was evident for 
the primary composite CV outcome (MI, stroke, and CV death) and also for
 the expanded composite CV outcome (plus coronary revascularization and 
hospitalization for unstable angina or heart failure). For all 
components of the primary and expanded composite CV outcome, and notably
 for all-cause death, the estimated treatment effect of liraglutide was 
numerically larger in those with eGFR &lt;60 mL/min/1.73 m<sup>2</sup>. 
When we subdivided eGFR and albuminuria subgroups more finely, we could 
not detect increasing benefits of liraglutide versus placebo with 
advancing CKD (see <a data-tab="pane-pcw-Figures" href="#F2" id="F2R" class="">Figure 2</a> and <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.036418">Figures II and III in the online-only Data Supplement</a>).
 Those observations, however, are hampered by reduced statistical power,
 particularly for the subgroup with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>,
 which included only 224 patients. Similarly, when analyzing eGFR as a 
continuous variable, no significant effect modification with liraglutide
 versus placebo on outcomes was observed. Again, those analyses are 
limited by the power of the interaction test and complexity of spline 
function (<a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.036418">Figure I in the online-only Data Supplement</a>).</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Because eGFR &lt;60 mL/min/1.73 m<sup>2</sup> was defined in the inclusion criteria of LEADER as equivalent to established CV disease<sup><a data-tab="pane-pcw-references" href="#R29" id="R29R" class="tab-link">29</a></sup> and the latter subgroup achieved increased CV benefit compared with the subgroup with high CV risk,<sup><a data-tab="pane-pcw-references" href="#R18" id="R18R" class="tab-link">18</a></sup> we also analyzed here subgroups with or without prior history of MI or stroke (<a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.036418">Figures IV and V in the online-only Data Supplement</a>). The benefit of liraglutide versus placebo in those with eGFR &lt;60 mL/min/1.73 m<sup>2</sup> appeared to be numerically greater (compared with those who had eGFR ≥60 mL/min/1.73 m<sup>2</sup>) in patients with and without prior MI or stroke (<a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.036418">Figure IV in the online-only Data Supplement</a>).</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">There
 were no differences in the effectiveness of liraglutide in those with 
and without albuminuria. This was true for the primary composite CV 
outcome, as well as for the expanded composite CV outcome, all MIs and 
all-cause death (interaction <i>P</i> not significant for all outcomes).
 This pattern was not substantially altered when subgroups of micro- and
 macroalbuminuria were considered separately or when subgroups defined 
by both eGFR and albuminuria categories were analyzed (<a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.036418">Figures II and III in the online-only Data Supplement</a>).</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">The
 current analyses revealed no new safety issues with liraglutide 
treatment in patients with CKD. There were no indications that 
occurrence of serious adverse events was greater with liraglutide than 
with placebo in either renal subgroup. It is already known that 
liraglutide is associated with a lower risk of hypoglycemia compared 
with placebo with uneven addition of other antihyperglycemic 
medications. That difference, in absolute terms, appeared to increase 
with lower eGFR, which is consistent with previous results.<sup><a data-tab="pane-pcw-references" href="#R32" id="R32R" class="tab-link">32</a></sup></p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Liraglutide had pronounced lowering effects on HbA<sub>1c</sub>
 and weight and slight lowering effects on systolic blood pressure and 
low-density lipoprotein cholesterol. Those effects did not appear to be 
different in those with or without low eGFR or micro- and 
macroalbuminuria, whereas the modest blood pressure–lowering effect of 
liraglutide may be confined to those with normal eGFR and 
normoalbuminuria. Liraglutide is not eliminated by the kidney, and its 
pharmacokinetics appear to be unchanged with decreasing eGFR.<sup><a data-tab="pane-pcw-references" href="#R33" id="R33R" class="tab-link">33</a></sup> Therefore, enhanced availability of the medication in CKD is unlikely to play a role.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Post
 hoc data from the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular 
Outcomeb Event Trial in Type 2 Diabetes Mellitus Patients) reported on 
effects of the SGLT-2 inhibitor empagliflozin versus placebo in 
subgroups with low eGFR (30–60 mL/min/1.73 m<sup>2</sup>).<sup><a data-tab="pane-pcw-references" href="#R34" id="R34R" class="tab-link">34</a></sup>
 Empagliflozin was as effective on CV outcomes and all-cause death in 
those with as without diabetic kidney disease. Similar findings of the 
SGLT-2 inhibitor canagliflozin have recently been reported in a 
subpopulation with baseline eGFR between 30 and 60 mL/min/1.73 m<sup>2</sup>.<sup><a data-tab="pane-pcw-references" href="#R21" id="R21R" class="tab-link">21</a></sup> Empagliflozin is not indicated for use in patients with an eGFR &lt;45 mL/min/1.73 m<sup>2</sup>,<sup><a data-tab="pane-pcw-references" href="#R35" id="R35R" class="tab-link">35</a></sup> and canagliflozin is not recommended to be initiated in patients with an eGFR &lt;45 mL/min/1.73 m<sup>2</sup><sup><a data-tab="pane-pcw-references" href="#R36" id="R36R" class="tab-link">36</a></sup> because their antihyperglycemic action is blunted with low eGFR. However, the latter restrictions may change in due course.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Given the proven CV benefit of liraglutide,<sup><a data-tab="pane-pcw-references" href="#R27" id="R27R" class="tab-link">27</a>,<a data-tab="pane-pcw-references" href="#R37" id="R37R" class="tab-link">37</a></sup> updated guidelines such as those from the American Diabetes Association<sup><a data-tab="pane-pcw-references" href="#R38" id="R38R" class="tab-link">38</a></sup>
 and recent commentaries suggest that liraglutide should be considered 
as a preferred second-line option for the treatment of T2DM, 
particularly in patients who have established CV disease or are at high 
risk of developing CV disease.<sup><a data-tab="pane-pcw-references" href="#R39" id="R39R" class="tab-link">39</a></sup>
 The aim is to achieve glycemic targets as well as improve CV outcomes. 
Some authors also recommend that patients with T2DM and stage 3 CKD are 
particularly suited to liraglutide therapy.<sup><a data-tab="pane-pcw-references" href="#R39" id="R39R" class="tab-link">39</a></sup>
 Our findings do not contradict this idea and suggest that liraglutide 
may be beneficial in patients with CKD. The latter is clinically 
important because patients with diabetes mellitus and reduced eGFR have a
 high CV burden but a substantially restricted list of antihyperglycemic
 agents because of increased risk of adverse events (eg, metformin), 
less metabolic efficacy (eg, SGLT-2 inhibitors), or pharmacokinetics 
(eg, some sulfonylureas).</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Some
 limitations must be considered when interpreting the current post hoc 
subgroup analyses. Such analyses can only be hypothesis-forming, and 
those hypotheses need to be examined in dedicated trials. LEADER was 
powered to analyze the primary composite CV outcome in all patients. 
Thus, testing multiple secondary CV outcomes in a subgroup analysis may 
be susceptible to both a lack of power and issues related to multiple 
comparisons; as such, significant results may be chance findings.</p>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">In
 conclusion, these analyses show that in the context of comprehensive 
standard of care, liraglutide treatment of patients with T2DM and CKD at
 high CV risk leads to a reduction in diverse CV outcomes and all-cause 
mortality, in line with the overall results of the trial. The benefits 
are evident in those with and without CKD. The risk of adverse events 
observed with liraglutide compared with placebo did not differ across 
those with or without renal risks.</p>
<h3 class="article-section__title to-section " id="d3e2804">Acknowledgments</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">Part
 of these data have been published in the form of an abstract for the 
American Heart Association (2017) 90th Scientific Session (<i>Circulation</i>
 2017;136(Suppl 1):A15035). Medical writing and submission support were 
provided by Nathan Ley of Watermeadow Medical, an Ashfield company, part
 of UDG Healthcare plc, funded by Novo Nordisk. J.F.E.M. had full access
 to all the data in the study and takes responsibility for the integrity
 of the data and the accuracy of the data analysis. All authors had 
access to the final study results. J.F.E.M., B.J.v.S., and T.I. drafted 
this manuscript, which was revised and approved by all authors, who also
 assume responsibility for its content. We also thank the participants, 
investigators, trial site staff, and leadership, employees, and 
contractors of the sponsor who were involved in the conduct of the 
trial.</p>
<div class="articleInformation">
<h3 class="article-section__title to-section " id="d3e2815">Sources of Funding</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">This study was funded by Novo Nordisk.</p>
</div>
<div class="articleInformation">
<h3 class="article-section__title to-section " id="d3e2823">Disclosures</h3>
<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">J.F.E.M.
 reports receipt of speaker honoraria from Amgen, AstraZeneca, 
Boehringer Ingelheim, Braun, Eli Lilly &amp; Co, Fresenius, Gambro, 
Medice, Novo Nordisk, Relypsa, and Roche; research support from 
Boehringer Ingelheim, the Canadian Institutes Health Research, Celgene, 
the European Union, Novo Nordisk, Roche, and Sandoz; and consultation 
fees from AstraZeneca, Bayer, Celgene, Eli Lilly &amp; Co, Fresenius, 
Lanthio Pharma, Novo Nordisk, Relypsa, Sanifit, and Vifor Pharma. V.F. 
reports receipt of consultation fees from Abbott, AstraZeneca, 
Boehringer Ingelheim, Eli Lilly &amp; Co, Janssen, Intarcia Therapeutics
 Takeda, Novo Nordisk, Pamlab, and Sanofi; speaker honoraria from 
AstraZeneca, Sanofi, and Takeda; and research grants from Asahi, Abbott,
 Bayer, Eli Lilly &amp; Co, Endo Barrier, Gilead Sciences, and Novo 
Nordisk. O.M. reports attendance at advisory boards for AstraZeneca, 
Boehringer Ingelheim, Eli Lilly &amp; Co, Janssen, Merck Sharp &amp; 
Dohme, Novartis, Novo Nordisk, and Sanofi; grants paid to institution as
 a study physician by AstraZeneca/Bristol-Myers Squibb; receipt of 
research grant support through Hadassah Hebrew University Hospital from 
Novo Nordisk; and speaker honoraria from AstraZeneca/Bristol-Myers 
Squibb, Boehringer Ingelheim, Eli Lilly &amp; Co, Merck Sharp &amp; 
Dohme, Novartis, Novo Nordisk, and Sanofi. I.R. reports attendance at 
advisory boards for AstraZeneca/Bristol-Myers Squibb, Eli Lilly &amp; 
Co, Labstyle Innovations Ltd, Medscape LLC, Merck Sharp &amp; Dohme, 
Novo Nordisk, Orgenesis, Sanofi, and SmartZyme Innovation Ltd; receipt 
of consultation fees from AstraZeneca/Bristol-Myers Squibb, FuturRx Gili
 Medical, Insuline Medical, and Kamada Ltd,; speaker honoraria from 
AstraZeneca/Bristol-Myers Squibb, Eli Lilly &amp; Co, Johnson &amp; 
Johnson, Merck Sharp &amp; Dohme, Novartis, Novo Nordisk, Sanofi, and 
Teva Pharmaceutical Industries; and being a stock/shareholder in GlucoMe
 Ltd, Insuline Medical, Labstyle Innovations Ltd, SmartZyme Innovation 
Ltd, and Orgenesis. B.G., T.I., and B.J.v.S. report being full-time 
employees of Novo Nordisk. N.R.P. reports receipt of speaker and 
advisory board honoraria from AstraZeneca (concerning diabetes 
mellitus), Novo Nordisk, Servier, and Takeda; and research grants for 
his research group (relating to T2DM) from the British Heart Foundation,
 Diabetes UK, Julius Clinical, and the National Institute for Health 
Research Efficacy and Mechanism Evaluation.</p>
</div>
<h3 class="article-section__title to-section " id="d4423e170">Footnotes</h3>
<div class="NLM_author-notes">
<fn xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" fn-type="financial-disclosure" id="fn01"><p>Sources of Funding, see page 2917</p></fn><fn xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" fn-type="supplementary-material" id="fn02"><p>The online-only Data Supplement is available with this article at <a class="references__uri" href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.036418">https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.036418</a>.</p></fn><fn xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" fn-type="other" id="fn03"><p><a class="references__uri" href="https://www.ahajournals.org/journal/circ">https://www.ahajournals.org/journal/circ</a></p></fn><div class="NLM_corresp">Johannes F.E. Mann, MD, KfH Kidney Center, 15, Isoldenstrasse, Munchen 80804, Germany. Email <a class="references__email" href="mailto:prof.j.mann@gmail.com"><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:urlutil="java:com.atypon.literatum.customization.UrlUtil" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="nobrWithWbr">prof.<wbr xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">j.<wbr xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">mann@gmail.<wbr xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns">com</wbr></wbr></wbr></span></a>
</div>
</div>
<div class="article__references">
<p class="explanation__text"></p>
<h2 class="article-section__title to-section" id="d4423e1998">References</h2>
<ul class="rlist separator">
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R1R" class="tab-link-return ref__number"><span class="label">1. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Nasri H</person-group>. <span class="references__article-title">On the occasion of the world diabetes day 2013; diabetes education and prevention; a nephrology point of view.</span><span class="references__source"><strong>J Renal Inj Prev</strong></span>. <span class="references__year">2013</span>; 2:31–32. doi: 10.12861/jrip.2013.11<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_2_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=25340120" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=2&amp;publication_year=2013&amp;pages=31-32&amp;journal=J+Renal+Inj+Prev&amp;author=H+Nasri&amp;title=On+the+occasion+of+the+world+diabetes+day+2013%3B+diabetes+education+and+prevention%3B+a+nephrology+point+of+view." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R2R" class="tab-link-return ref__number"><span class="label">2. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, Tonelli M</person-group>; Alberta Kidney Disease Network. <span class="references__article-title">Cause of death in patients with reduced kidney function.</span><span class="references__source"><strong>J Am Soc Nephrol</strong></span>. <span class="references__year">2015</span>; 26:2504–2511. doi: 10.1681/ASN.2014070714<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_3_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1681%2FASN.2014070714" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_3_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=25733525" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=26&amp;publication_year=2015&amp;pages=2504-2511&amp;journal=J+Am+Soc+Nephrol&amp;author=S+Thompson&amp;author=M+James&amp;author=N+Wiebe&amp;author=B+Hemmelgarn&amp;author=B+Manns&amp;author=S+Klarenbach&amp;author=M+Tonelli&amp;title=Cause+of+death+in+patients+with+reduced+kidney+function." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R3R" class="tab-link-return ref__number"><span class="label">3. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Muntner
 P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, O’Connor A, 
Perumal K, Rahman M, Steigerwalt S, Teal V, Townsend R, Weir M, Wright 
JT</person-group>; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. <span class="references__article-title">Hypertension
 awareness, treatment, and control in adults with CKD: results from the 
Chronic Renal Insufficiency Cohort (CRIC) study.</span><span class="references__source"><strong>Am J Kidney Dis</strong></span>. <span class="references__year">2010</span>; 55:441–451. doi: 10.1053/j.ajkd.2009.09.014<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_4_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1053%2Fj.ajkd.2009.09.014" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_4_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=19962808" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=55&amp;publication_year=2010&amp;pages=441-451&amp;journal=Am+J+Kidney+Dis&amp;author=P+Muntner&amp;author=A+Anderson&amp;author=J+Charleston&amp;author=Z+Chen&amp;author=V+Ford&amp;author=G+Makos&amp;author=A+O%E2%80%99Connor&amp;author=K+Perumal&amp;author=M+Rahman&amp;author=S+Steigerwalt&amp;author=V+Teal&amp;author=R+Townsend&amp;author=M+Weir&amp;author=JT+Wright&amp;title=Hypertension+awareness%2C+treatment%2C+and+control+in+adults+with+CKD%3A+results+from+the+Chronic+Renal+Insufficiency+Cohort+%28CRIC%29+study." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R4R" class="tab-link-return ref__number"><span class="label">4. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Ninomiya
 T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, 
Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, 
Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J</person-group>; ADVANCE Collaborative Group. <span class="references__article-title">Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.</span><span class="references__source"><strong>J Am Soc Nephrol</strong></span>. <span class="references__year">2009</span>; 20:1813–1821. doi: 10.1681/ASN.2008121270<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_5_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1681%2FASN.2008121270" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_5_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=19443635" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=20&amp;publication_year=2009&amp;pages=1813-1821&amp;journal=J+Am+Soc+Nephrol&amp;author=T+Ninomiya&amp;author=V+Perkovic&amp;author=BE+de+Galan&amp;author=S+Zoungas&amp;author=A+Pillai&amp;author=M+Jardine&amp;author=A+Patel&amp;author=A+Cass&amp;author=B+Neal&amp;author=N+Poulter&amp;author=CE+Mogensen&amp;author=M+Cooper&amp;author=M+Marre&amp;author=B+Williams&amp;author=P+Hamet&amp;author=G+Mancia&amp;author=M+Woodward&amp;author=S+Macmahon&amp;author=J+Chalmers&amp;title=Albuminuria+and+kidney+function+independently+predict+cardiovascular+and+renal+outcomes+in+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R5R" class="tab-link-return ref__number"><span class="label">5. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">van
 der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de 
Jong P, Gansevoort RT, van der Velde M, Matsushita K, Coresh J, Astor 
BC, Woodward M, Levey AS, de Jong PE, Gansevoort RT, Levey A, El-Nahas 
M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli 
M, Hemmelgarn B, Sacks F, Curhan G, Collins AJ, Li S, Chen SC, Hawaii 
Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen K, Mann JF, Yusuf S, Teo
 KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, Kleefstra N, 
Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley
 T</person-group>; Chronic Kidney Disease Prognosis Consortium. <span class="references__article-title">Lower
 estimated glomerular filtration rate and higher albuminuria are 
associated with all-cause and cardiovascular mortality: a collaborative 
meta-analysis of high-risk population cohorts.</span><span class="references__source"><strong>Kidney Int</strong></span>. <span class="references__year">2011</span>; 79:1341–1352. doi: 10.1038/ki.2010.536<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_6_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1038%2Fki.2010.536" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_6_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=21307840" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=79&amp;publication_year=2011&amp;pages=1341-1352&amp;journal=Kidney+Int&amp;author=M+van+der+Velde&amp;author=K+Matsushita&amp;author=J+Coresh&amp;author=BC+Astor&amp;author=M+Woodward&amp;author=A+Levey&amp;author=P+de+Jong&amp;author=RT+Gansevoort&amp;author=M+van+der+Velde&amp;author=K+Matsushita&amp;author=J+Coresh&amp;author=BC+Astor&amp;author=M+Woodward&amp;author=AS+Levey&amp;author=PE+de+Jong&amp;author=RT+Gansevoort&amp;author=A+Levey&amp;author=M+El-Nahas&amp;author=KU+Eckardt&amp;author=BL+Kasiske&amp;author=T+Ninomiya&amp;author=J+Chalmers&amp;author=S+Macmahon&amp;author=M+Tonelli&amp;author=B+Hemmelgarn&amp;author=F+Sacks&amp;author=G+Curhan&amp;author=AJ+Collins&amp;author=S+Li&amp;author=SC+Chen&amp;author=KP+Hawaii+Cohort&amp;author=BJ+Lee&amp;author=A+Ishani&amp;author=J+Neaton&amp;author=K+Svendsen&amp;author=JF+Mann&amp;author=S+Yusuf&amp;author=KK+Teo&amp;author=P+Gao&amp;author=RG+Nelson&amp;author=WC+Knowler&amp;author=HJ+Bilo&amp;author=H+Joosten&amp;author=N+Kleefstra&amp;author=KH+Groenier&amp;author=P+Auguste&amp;author=K+Veldhuis&amp;author=Y+Wang&amp;author=L+Camarata&amp;author=B+Thomas&amp;author=T+Manley&amp;title=Lower+estimated+glomerular+filtration+rate+and+higher+albuminuria+are+associated+with+all-cause+and+cardiovascular+mortality%3A+a+collaborative+meta-analysis+of+high-risk+population+cohorts." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R6R" class="tab-link-return ref__number"><span class="label">6. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S</person-group>. <span class="references__article-title">Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.</span><span class="references__source"><strong>Ann Intern Med</strong></span>. <span class="references__year">2001</span>; 134:629–636<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_7_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.7326%2F0003-4819-134-8-200104170-00007" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_7_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=11304102" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=134&amp;publication_year=2001&amp;pages=629-636&amp;journal=Ann+Intern+Med&amp;author=JF+Mann&amp;author=HC+Gerstein&amp;author=J+Pogue&amp;author=J+Bosch&amp;author=S+Yusuf&amp;title=Renal+insufficiency+as+a+predictor+of+cardiovascular+outcomes+and+the+impact+of+ramipril%3A+the+HOPE+randomized+trial." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R7R" class="tab-link-return ref__number"><span class="label">7. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S</person-group>; HOPE Study Investigators. <span class="references__article-title">Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.</span><span class="references__source"><strong>JAMA</strong></span>. <span class="references__year">2001</span>; 286:421–426<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_8_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1001%2Fjama.286.4.421" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_8_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=11466120" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=286&amp;publication_year=2001&amp;pages=421-426&amp;journal=JAMA&amp;author=HC+Gerstein&amp;author=JF+Mann&amp;author=Q+Yi&amp;author=B+Zinman&amp;author=SF+Dinneen&amp;author=B+Hoogwerf&amp;author=JP+Hall%C3%A9&amp;author=J+Young&amp;author=A+Rashkow&amp;author=C+Joyce&amp;author=S+Nawaz&amp;author=S+Yusuf&amp;title=Albuminuria+and+risk+of+cardiovascular+events%2C+death%2C+and+heart+failure+in+diabetic+and+nondiabetic+individuals." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R8R" class="tab-link-return ref__number"><span class="label">8. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Baigent
 C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, 
Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, 
Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, 
Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, 
Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D,
 Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, 
Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C,
 Parish S, Simpson D, Sleight P, Young A, Collins R</person-group>; SHARP Investigators. <span class="references__article-title">The
 effects of lowering LDL cholesterol with simvastatin plus ezetimibe in 
patients with chronic kidney disease (Study of Heart and Renal 
Protection): a randomised placebo-controlled trial.</span><span class="references__source"><strong>Lancet</strong></span>. <span class="references__year">2011</span>; 377:2181–2192. doi: 10.1016/S0140-6736(11)60739-3<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1016%2FS0140-6736%2811%2960739-3" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=21663949" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=377&amp;publication_year=2011&amp;pages=2181-2192&amp;journal=Lancet&amp;author=C+Baigent&amp;author=MJ+Landray&amp;author=C+Reith&amp;author=J+Emberson&amp;author=DC+Wheeler&amp;author=C+Tomson&amp;author=C+Wanner&amp;author=V+Krane&amp;author=A+Cass&amp;author=J+Craig&amp;author=B+Neal&amp;author=L+Jiang&amp;author=LS+Hooi&amp;author=A+Levin&amp;author=L+Agodoa&amp;author=M+Gaziano&amp;author=B+Kasiske&amp;author=R+Walker&amp;author=ZA+Massy&amp;author=B+Feldt-Rasmussen&amp;author=U+Krairittichai&amp;author=V+Ophascharoensuk&amp;author=B+Fellstr%C3%B6m&amp;author=H+Holdaas&amp;author=V+Tesar&amp;author=A+Wiecek&amp;author=D+Grobbee&amp;author=D+de+Zeeuw&amp;author=C+Gr%C3%B6nhagen-Riska&amp;author=T+Dasgupta&amp;author=D+Lewis&amp;author=W+Herrington&amp;author=M+Mafham&amp;author=W+Majoni&amp;author=K+Wallendszus&amp;author=R+Grimm&amp;author=T+Pedersen&amp;author=J+Tobert&amp;author=J+Armitage&amp;author=A+Baxter&amp;author=C+Bray&amp;author=Y+Chen&amp;author=Z+Chen&amp;author=M+Hill&amp;author=C+Knott&amp;author=S+Parish&amp;author=D+Simpson&amp;author=P+Sleight&amp;author=A+Young&amp;author=R+Collins&amp;title=The+effects+of+lowering+LDL+cholesterol+with+simvastatin+plus+ezetimibe+in+patients+with+chronic+kidney+disease+%28Study+of+Heart+and+Renal+Protection%29%3A+a+randomised+placebo-controlled+trial." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R9R" class="tab-link-return ref__number"><span class="label">9. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Fellström
 BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae 
DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer 
G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, 
Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, 
Gottlow M, Johnsson E, Zannad F</person-group>; AURORA Study Group. <span class="references__article-title">Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2009</span>; 360:1395–1407. doi: 10.1056/NEJMoa0810177<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_10_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa0810177" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_10_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=19332456" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=360&amp;publication_year=2009&amp;pages=1395-1407&amp;journal=N+Engl+J+Med&amp;author=BC+Fellstr%C3%B6m&amp;author=AG+Jardine&amp;author=RE+Schmieder&amp;author=H+Holdaas&amp;author=K+Bannister&amp;author=J+Beutler&amp;author=DW+Chae&amp;author=A+Chevaile&amp;author=SM+Cobbe&amp;author=C+Gr%C3%B6nhagen-Riska&amp;author=JJ+De+Lima&amp;author=R+Lins&amp;author=G+Mayer&amp;author=AW+McMahon&amp;author=HH+Parving&amp;author=G+Remuzzi&amp;author=O+Samuelsson&amp;author=S+Sonkodi&amp;author=D+Sci&amp;author=G+S%C3%BCleymanlar&amp;author=D+Tsakiris&amp;author=V+Tesar&amp;author=V+Todorov&amp;author=A+Wiecek&amp;author=RP+W%C3%BCthrich&amp;author=M+Gottlow&amp;author=E+Johnsson&amp;author=F+Zannad&amp;title=Rosuvastatin+and+cardiovascular+events+in+patients+undergoing+hemodialysis." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R10R" class="tab-link-return ref__number"><span class="label">10. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E</person-group>; German Diabetes and Dialysis Study Investigators. <span class="references__article-title">Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2005</span>; 353:238–248. doi: 10.1056/NEJMoa043545<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_11_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa043545" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_11_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=16034009" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=353&amp;publication_year=2005&amp;pages=238-248&amp;journal=N+Engl+J+Med&amp;author=C+Wanner&amp;author=V+Krane&amp;author=W+M%C3%A4rz&amp;author=M+Olschewski&amp;author=JF+Mann&amp;author=G+Ruf&amp;author=E+Ritz&amp;title=Atorvastatin+in+patients+with+type+2+diabetes+mellitus+undergoing+hemodialysis." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R11R" class="tab-link-return ref__number"><span class="label">11. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J</person-group>; Collaborators on Trials of Lowering Glucose (CONTROL) group. <span class="references__article-title">Effects
 of intensive glucose control on microvascular outcomes in patients with
 type 2 diabetes: a meta-analysis of individual participant data from 
randomised controlled trials.</span><span class="references__source"><strong>Lancet Diabetes Endocrinol</strong></span>. <span class="references__year">2017</span>; 5:431–437. doi: 10.1016/S2213-8587(17)30104-3<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_12_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1016%2FS2213-8587%2817%2930104-3" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_12_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=28365411" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=5&amp;publication_year=2017&amp;pages=431-437&amp;journal=Lancet+Diabetes+Endocrinol&amp;author=S+Zoungas&amp;author=H+Arima&amp;author=HC+Gerstein&amp;author=RR+Holman&amp;author=M+Woodward&amp;author=P+Reaven&amp;author=RA+Hayward&amp;author=T+Craven&amp;author=RL+Coleman&amp;author=J+Chalmers&amp;title=Effects+of+intensive+glucose+control+on+microvascular+outcomes+in+patients+with+type+2+diabetes%3A+a+meta-analysis+of+individual+participant+data+from+randomised+controlled+trials." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R12R" class="tab-link-return ref__number"><span class="label">12. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Turnbull
 FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, 
Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel 
AA, Paul SK, Travert F, Woodward M</person-group>. <span class="references__article-title">Intensive glucose control and macrovascular outcomes in type 2 diabetes.</span><span class="references__source"><strong>Diabetologia</strong></span>. <span class="references__year">2009</span>; 52:2288–2298. doi: 10.1007/s00125-009-1470-0<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_13_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1007%2Fs00125-009-1470-0" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_13_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=19655124" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=52&amp;publication_year=2009&amp;pages=2288-2298&amp;journal=Diabetologia&amp;author=FM+Turnbull&amp;author=C+Abraira&amp;author=RJ+Anderson&amp;author=RP+Byington&amp;author=JP+Chalmers&amp;author=WC+Duckworth&amp;author=GW+Evans&amp;author=HC+Gerstein&amp;author=RR+Holman&amp;author=TE+Moritz&amp;author=BC+Neal&amp;author=T+Ninomiya&amp;author=AA+Patel&amp;author=SK+Paul&amp;author=F+Travert&amp;author=M+Woodward&amp;title=Intensive+glucose+control+and+macrovascular+outcomes+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R13R" class="tab-link-return ref__number"><span class="label">13. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Gerstein
 HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, 
Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S</person-group>; ORIGIN Trial Investigators. <span class="references__article-title">Basal insulin and cardiovascular and other outcomes in dysglycemia.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2012</span>; 367:319–328. doi: 10.1056/NEJMoa1203858<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_14_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1203858" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_14_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=22686416" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=367&amp;publication_year=2012&amp;pages=319-328&amp;journal=N+Engl+J+Med&amp;author=HC+Gerstein&amp;author=J+Bosch&amp;author=GR+Dagenais&amp;author=R+D%C3%ADaz&amp;author=H+Jung&amp;author=AP+Maggioni&amp;author=J+Pogue&amp;author=J+Probstfield&amp;author=A+Ramachandran&amp;author=MC+Riddle&amp;author=LE+Ryd%C3%A9n&amp;author=S+Yusuf&amp;title=Basal+insulin+and+cardiovascular+and+other+outcomes+in+dysglycemia." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R14R" class="tab-link-return ref__number"><span class="label">14. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Marso
 SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley 
RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, 
Buse JB</person-group>; DEVOTE Study Group. <span class="references__article-title">Efficacy and safety of degludec versus glargine in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2017</span>; 377:723–732. doi: 10.1056/NEJMoa1615692<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_15_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1615692" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_15_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=28605603" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=377&amp;publication_year=2017&amp;pages=723-732&amp;journal=N+Engl+J+Med&amp;author=SP+Marso&amp;author=DK+McGuire&amp;author=B+Zinman&amp;author=NR+Poulter&amp;author=SS+Emerson&amp;author=TR+Pieber&amp;author=RE+Pratley&amp;author=PM+Haahr&amp;author=M+Lange&amp;author=K+Brown-Frandsen&amp;author=A+Moses&amp;author=S+Skibsted&amp;author=K+Kvist&amp;author=JB+Buse&amp;title=Efficacy+and+safety+of+degludec+versus+glargine+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R15R" class="tab-link-return ref__number"><span class="label">15. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Scirica
 BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, 
Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, 
Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I</person-group>; SAVOR-TIMI 53 Steering Committee and Investigators. <span class="references__article-title">Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2013</span>; 369:1317–1326. doi: 10.1056/NEJMoa1307684<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_16_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1307684" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_16_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=23992601" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=369&amp;publication_year=2013&amp;pages=1317-1326&amp;journal=N+Engl+J+Med&amp;author=BM+Scirica&amp;author=DL+Bhatt&amp;author=E+Braunwald&amp;author=PG+Steg&amp;author=J+Davidson&amp;author=B+Hirshberg&amp;author=P+Ohman&amp;author=R+Frederich&amp;author=SD+Wiviott&amp;author=EB+Hoffman&amp;author=MA+Cavender&amp;author=JA+Udell&amp;author=NR+Desai&amp;author=O+Mosenzon&amp;author=DK+McGuire&amp;author=KK+Ray&amp;author=LA+Leiter&amp;author=I+Raz&amp;title=Saxagliptin+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes+mellitus." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R16R" class="tab-link-return ref__number"><span class="label">16. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">White
 WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez 
AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F</person-group>; EXAMINE Investigators. <span class="references__article-title">Alogliptin after acute coronary syndrome in patients with type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2013</span>; 369:1327–1335. doi: 10.1056/NEJMoa1305889<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_17_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1305889" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_17_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=23992602" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=369&amp;publication_year=2013&amp;pages=1327-1335&amp;journal=N+Engl+J+Med&amp;author=WB+White&amp;author=CP+Cannon&amp;author=SR+Heller&amp;author=SE+Nissen&amp;author=RM+Bergenstal&amp;author=GL+Bakris&amp;author=AT+Perez&amp;author=PR+Fleck&amp;author=CR+Mehta&amp;author=S+Kupfer&amp;author=C+Wilson&amp;author=WC+Cushman&amp;author=F+Zannad&amp;title=Alogliptin+after+acute+coronary+syndrome+in+patients+with+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R17R" class="tab-link-return ref__number"><span class="label">17. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Green
 JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, 
Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl 
E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR</person-group>; TECOS Study Group. <span class="references__article-title">Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2015</span>; 373:232–242. doi: 10.1056/NEJMoa1501352<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_18_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1501352" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_18_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=26052984" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=373&amp;publication_year=2015&amp;pages=232-242&amp;journal=N+Engl+J+Med&amp;author=JB+Green&amp;author=MA+Bethel&amp;author=PW+Armstrong&amp;author=JB+Buse&amp;author=SS+Engel&amp;author=J+Garg&amp;author=R+Josse&amp;author=KD+Kaufman&amp;author=J+Koglin&amp;author=S+Korn&amp;author=JM+Lachin&amp;author=DK+McGuire&amp;author=MJ+Pencina&amp;author=E+Standl&amp;author=PP+Stein&amp;author=S+Suryawanshi&amp;author=F+Van+de+Werf&amp;author=ED+Peterson&amp;author=RR+Holman&amp;title=Effect+of+sitagliptin+on+cardiovascular+outcomes+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R18R" class="tab-link-return ref__number"><span class="label">18. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Marso
 SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, 
Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, 
Zinman B, Bergenstal RM, Buse JB</person-group>; LEADER Steering Committee; LEADER Trial Investigators. <span class="references__article-title">Liraglutide and cardiovascular outcomes in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2016</span>; 375:311–322. doi: 10.1056/NEJMoa1603827<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_19_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1603827" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_19_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=27295427" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=375&amp;publication_year=2016&amp;pages=311-322&amp;journal=N+Engl+J+Med&amp;author=SP+Marso&amp;author=GH+Daniels&amp;author=K+Brown-Frandsen&amp;author=P+Kristensen&amp;author=JF+Mann&amp;author=MA+Nauck&amp;author=SE+Nissen&amp;author=S+Pocock&amp;author=NR+Poulter&amp;author=LS+Ravn&amp;author=WM+Steinberg&amp;author=M+Stockner&amp;author=B+Zinman&amp;author=RM+Bergenstal&amp;author=JB+Buse&amp;title=Liraglutide+and+cardiovascular+outcomes+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R19R" class="tab-link-return ref__number"><span class="label">19. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Marso
 SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I,
 Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, 
Pettersson J, Vilsbøll T</person-group>; SUSTAIN-6 Investigators. <span class="references__article-title">Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2016</span>; 375:1834–1844. doi: 10.1056/NEJMoa1607141<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_20_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1607141" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_20_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=27633186" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=375&amp;publication_year=2016&amp;pages=1834-1844&amp;journal=N+Engl+J+Med&amp;author=SP+Marso&amp;author=SC+Bain&amp;author=A+Consoli&amp;author=FG+Eliaschewitz&amp;author=E+J%C3%B3dar&amp;author=LA+Leiter&amp;author=I+Lingvay&amp;author=J+Rosenstock&amp;author=J+Seufert&amp;author=ML+Warren&amp;author=V+Woo&amp;author=O+Hansen&amp;author=AG+Holst&amp;author=J+Pettersson&amp;author=T+Vilsb%C3%B8ll&amp;title=Semaglutide+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R20R" class="tab-link-return ref__number"><span class="label">20. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Zinman
 B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, 
Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE</person-group>; EMPA-REG OUTCOME Investigators. <span class="references__article-title">Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2015</span>; 373:2117–2128. doi: 10.1056/NEJMoa1504720<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_21_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1504720" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_21_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=26378978" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=373&amp;publication_year=2015&amp;pages=2117-2128&amp;journal=N+Engl+J+Med&amp;author=B+Zinman&amp;author=C+Wanner&amp;author=JM+Lachin&amp;author=D+Fitchett&amp;author=E+Bluhmki&amp;author=S+Hantel&amp;author=M+Mattheus&amp;author=T+Devins&amp;author=OE+Johansen&amp;author=HJ+Woerle&amp;author=UC+Broedl&amp;author=SE+Inzucchi&amp;title=Empagliflozin%2C+cardiovascular+outcomes%2C+and+mortality+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R21R" class="tab-link-return ref__number"><span class="label">21. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR</person-group>; CANVAS Program Collaborative Group. <span class="references__article-title">Canagliflozin and cardiovascular and renal events in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2017</span>; 377:644–657. doi: 10.1056/NEJMoa1611925<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_22_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1611925" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_22_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=28605608" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=377&amp;publication_year=2017&amp;pages=644-657&amp;journal=N+Engl+J+Med&amp;author=B+Neal&amp;author=V+Perkovic&amp;author=KW+Mahaffey&amp;author=G+Fulcher&amp;author=N+Erondu&amp;author=W+Shaw&amp;author=G+Law&amp;author=M+Desai&amp;author=DR+Matthews&amp;title=Canagliflozin+and+cardiovascular+and+renal+events+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R22R" class="tab-link-return ref__number"><span class="label">22. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Engel
 SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, 
Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR</person-group>; TECOS Study Group. <span class="references__article-title">Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.</span><span class="references__source"><strong>Diabetes Obes Metab</strong></span>. <span class="references__year">2017</span>; 19:1587–1593. doi: 10.1111/dom.12983<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_23_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1111%2Fdom.12983" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_23_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=28432745" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=19&amp;publication_year=2017&amp;pages=1587-1593&amp;journal=Diabetes+Obes+Metab&amp;author=SS+Engel&amp;author=S+Suryawanshi&amp;author=SR+Stevens&amp;author=RG+Josse&amp;author=JH+Cornel&amp;author=N+Jakuboniene&amp;author=A+Riefflin&amp;author=T+Tankova&amp;author=J+Wainstein&amp;author=ED+Peterson&amp;author=RR+Holman&amp;title=Safety+of+sitagliptin+in+patients+with+type+2+diabetes+and+chronic+kidney+disease%3A+outcomes+from+TECOS." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R23R" class="tab-link-return ref__number"><span class="label">23. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Udell
 JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson 
JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini
 AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM</person-group>; SAVOR-TIMI 53 Steering Committee and Investigators. <span class="references__article-title">Saxagliptin
 and cardiovascular outcomes in patients with type 2 diabetes and 
moderate or severe renal impairment: observations from the SAVOR-TIMI 53
 Trial.</span><span class="references__source"><strong>Diabetes Care</strong></span>. <span class="references__year">2015</span>; 38:696–705. doi: 10.2337/dc14-1850<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_24_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=25552421" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=38&amp;publication_year=2015&amp;pages=696-705&amp;journal=Diabetes+Care&amp;author=JA+Udell&amp;author=DL+Bhatt&amp;author=E+Braunwald&amp;author=MA+Cavender&amp;author=O+Mosenzon&amp;author=PG+Steg&amp;author=JA+Davidson&amp;author=JC+Nicolau&amp;author=R+Corbalan&amp;author=B+Hirshberg&amp;author=R+Frederich&amp;author=K+Im&amp;author=AA+Umez-Eronini&amp;author=P+He&amp;author=DK+McGuire&amp;author=LA+Leiter&amp;author=I+Raz&amp;author=BM+Scirica&amp;title=Saxagliptin+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes+and+moderate+or+severe+renal+impairment%3A+observations+from+the+SAVOR-TIMI+53+Trial." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R24R" class="tab-link-return ref__number"><span class="label">24. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, Im K, Kanevsky E, Stahre C, Sjöstrand M, Raz I, Braunwald E</person-group>. <span class="references__article-title">Cardiovascular
 outcomes according to urinary albumin and kidney disease in patients 
with type 2 diabetes at high cardiovascular risk: observations from the 
SAVOR-TIMI 53 trial.</span><span class="references__source"><strong>JAMA Cardiol</strong></span>. <span class="references__year">2018</span>; 3:155–163. doi: 10.1001/jamacardio.2017.4228<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_25_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1001%2Fjamacardio.2017.4228" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_25_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=29214305" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=3&amp;publication_year=2018&amp;pages=155-163&amp;journal=JAMA+Cardiol&amp;author=BM+Scirica&amp;author=O+Mosenzon&amp;author=DL+Bhatt&amp;author=JA+Udell&amp;author=PG+Steg&amp;author=DK+McGuire&amp;author=K+Im&amp;author=E+Kanevsky&amp;author=C+Stahre&amp;author=M+Sj%C3%B6strand&amp;author=I+Raz&amp;author=E+Braunwald&amp;title=Cardiovascular+outcomes+according+to+urinary+albumin+and+kidney+disease+in+patients+with+type+2+diabetes+at+high+cardiovascular+risk%3A+observations+from+the+SAVOR-TIMI+53+trial." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R25R" class="tab-link-return ref__number"><span class="label">25. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B</person-group>; EMPA-REG OUTCOME Investigators. <span class="references__article-title">Empagliflozin
 and clinical outcomes in patients with type 2 diabetes mellitus, 
established cardiovascular disease, and chronic kidney disease.</span><span class="references__source"><strong>Circulation</strong></span>. <span class="references__year">2018</span>; 137:119–129. doi: 10.1161/CIRCULATIONAHA.117.028268<span class="references__suffix"><a href="https://www.ahajournals.org/doi/10.1161/circulationaha.117.028268" onclick="newWindow(this.href);return false" target="_blank">Link</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=137&amp;publication_year=2018&amp;pages=119-129&amp;journal=Circulation&amp;author=C+Wanner&amp;author=JM+Lachin&amp;author=SE+Inzucchi&amp;author=D+Fitchett&amp;author=M+Mattheus&amp;author=J+George&amp;author=HJ+Woerle&amp;author=UC+Broedl&amp;author=M+von+Eynatten&amp;author=B+Zinman&amp;title=Empagliflozin+and+clinical+outcomes+in+patients+with+type+2+diabetes+mellitus%2C+established+cardiovascular+disease%2C+and+chronic+kidney+disease." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R26R" class="tab-link-return ref__number"><span class="label">26. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Arnouts P, Bolignano D, Nistor I, Bilo H, Gnudi L, Heaf J, van Biesen W</person-group>. <span class="references__article-title">Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties.</span><span class="references__source"><strong>Nephrol Dial Transplant</strong></span>. <span class="references__year">2014</span>; 29:1284–1300. doi: 10.1093/ndt/gft462<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_27_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1093%2Fndt%2Fgft462" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_27_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=24322578" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=29&amp;publication_year=2014&amp;pages=1284-1300&amp;journal=Nephrol+Dial+Transplant&amp;author=P+Arnouts&amp;author=D+Bolignano&amp;author=I+Nistor&amp;author=H+Bilo&amp;author=L+Gnudi&amp;author=J+Heaf&amp;author=W+van+Biesen&amp;title=Glucose-lowering+drugs+in+patients+with+chronic+kidney+disease%3A+a+narrative+review+on+pharmacokinetic+properties." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R27R" class="tab-link-return ref__number"><span class="label">27. </span></a>FDA. <span class="references__article-title">Victoza US prescribing information.</span><span class="references__year">August 2017</span>. <a class="references__uri" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf</a>. Accessed March 14, 2018.<span class="references__suffix"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=August+2017&amp;title=Victoza+US+prescribing+information." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R28R" class="tab-link-return ref__number"><span class="label">28. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB</person-group>; LEADER Steering Committee and Investigators. <span class="references__article-title">Liraglutide and renal outcomes in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2017</span>; 377:839–848. doi: 10.1056/NEJMoa1616011<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_29_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1616011" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_29_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=28854085" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=377&amp;publication_year=2017&amp;pages=839-848&amp;journal=N+Engl+J+Med&amp;author=JFE+Mann&amp;author=DD+%C3%98rsted&amp;author=K+Brown-Frandsen&amp;author=SP+Marso&amp;author=NR+Poulter&amp;author=S+Rasmussen&amp;author=K+Torn%C3%B8e&amp;author=B+Zinman&amp;author=JB+Buse&amp;title=Liraglutide+and+renal+outcomes+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R29R" class="tab-link-return ref__number"><span class="label">29. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Marso
 SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, 
Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, 
Buse JB</person-group>. <span class="references__article-title">Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.</span><span class="references__source"><strong>Am Heart J</strong></span>. <span class="references__year">2013</span>; 166:823–30.e5. doi: 10.1016/j.ahj.2013.07.012<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_30_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1016%2Fj.ahj.2013.07.012" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_30_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=24176437" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=166&amp;publication_year=2013&amp;pages=823-30.e5&amp;journal=Am+Heart+J&amp;author=SP+Marso&amp;author=NR+Poulter&amp;author=SE+Nissen&amp;author=MA+Nauck&amp;author=B+Zinman&amp;author=GH+Daniels&amp;author=S+Pocock&amp;author=WM+Steinberg&amp;author=RM+Bergenstal&amp;author=JF+Mann&amp;author=LS+Ravn&amp;author=KB+Frandsen&amp;author=AC+Moses&amp;author=JB+Buse&amp;title=Design+of+the+liraglutide+effect+and+action+in+diabetes%3A+evaluation+of+cardiovascular+outcome+results+%28LEADER%29+trial." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R30R" class="tab-link-return ref__number"><span class="label">30. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Carrero
 JJ, Grams ME, Sang Y, Ärnlöv J, Gasparini A, Matsushita K, Qureshi AR, 
Evans M, Barany P, Lindholm B, Ballew SH, Levey AS, Gansevoort RT, 
Elinder CG, Coresh J</person-group>. <span class="references__article-title">Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality.</span><span class="references__source"><strong>Kidney Int</strong></span>. <span class="references__year">2017</span>; 91:244–251. doi: 10.1016/j.kint.2016.09.037<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_31_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1016%2Fj.kint.2016.09.037" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_31_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=27927597" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=91&amp;publication_year=2017&amp;pages=244-251&amp;journal=Kidney+Int&amp;author=JJ+Carrero&amp;author=ME+Grams&amp;author=Y+Sang&amp;author=J+%C3%84rnl%C3%B6v&amp;author=A+Gasparini&amp;author=K+Matsushita&amp;author=AR+Qureshi&amp;author=M+Evans&amp;author=P+Barany&amp;author=B+Lindholm&amp;author=SH+Ballew&amp;author=AS+Levey&amp;author=RT+Gansevoort&amp;author=CG+Elinder&amp;author=J+Coresh&amp;title=Albuminuria+changes+are+associated+with+subsequent+risk+of+end-stage+renal+disease+and+mortality." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R31R" class="tab-link-return ref__number"><span class="label">31. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis TM, Pardy C, Colman P, Keech A</person-group>. <span class="references__article-title">Estimated
 glomerular filtration rate and albuminuria are independent predictors 
of cardiovascular events and death in type 2 diabetes mellitus: the 
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.</span><span class="references__source"><strong>Diabetologia</strong></span>. <span class="references__year">2011</span>; 54:32–43. doi: 10.1007/s00125-010-1854-1<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_32_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1007%2Fs00125-010-1854-1" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_32_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=20668832" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=54&amp;publication_year=2011&amp;pages=32-43&amp;journal=Diabetologia&amp;author=PL+Drury&amp;author=R+Ting&amp;author=D+Zannino&amp;author=C+Ehnholm&amp;author=J+Flack&amp;author=M+Whiting&amp;author=R+Fassett&amp;author=JC+Ansquer&amp;author=P+Dixon&amp;author=TM+Davis&amp;author=C+Pardy&amp;author=P+Colman&amp;author=A+Keech&amp;title=Estimated+glomerular+filtration+rate+and+albuminuria+are+independent+predictors+of+cardiovascular+events+and+death+in+type+2+diabetes+mellitus%3A+the+Fenofibrate+Intervention+and+Event+Lowering+in+Diabetes+%28FIELD%29+study." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R32R" class="tab-link-return ref__number"><span class="label">32. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, Bosch-Traberg H, Syrén A, Umpierrez GE</person-group>. <span class="references__article-title">Efficacy
 and safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering 
Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment 
(LIRA-RENAL): a randomized clinical trial.</span><span class="references__source"><strong>Diabetes Care</strong></span>. <span class="references__year">2016</span>; 39:222–230. doi: 10.2337/dc14-2883<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_33_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=26681713" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=39&amp;publication_year=2016&amp;pages=222-230&amp;journal=Diabetes+Care&amp;author=MJ+Davies&amp;author=SC+Bain&amp;author=SL+Atkin&amp;author=P+Rossing&amp;author=D+Scott&amp;author=MS+Shamkhalova&amp;author=H+Bosch-Traberg&amp;author=A+Syr%C3%A9n&amp;author=GE+Umpierrez&amp;title=Efficacy+and+safety+of+Liraglutide+Versus+Placebo+as+Add-on+to+Glucose-Lowering+Therapy+in+Patients+With+Type+2+Diabetes+and+Moderate+Renal+Impairment+%28LIRA-RENAL%29%3A+a+randomized+clinical+trial." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R33R" class="tab-link-return ref__number"><span class="label">33. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M</person-group>. <span class="references__article-title">Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.</span><span class="references__source"><strong>Br J Clin Pharmacol</strong></span>. <span class="references__year">2009</span>; 68:898–905. doi: 10.1111/j.1365-2125.2009.03536.x<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_34_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1111%2Fj.1365-2125.2009.03536.x" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_34_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=20002084" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=68&amp;publication_year=2009&amp;pages=898-905&amp;journal=Br+J+Clin+Pharmacol&amp;author=LV+Jacobsen&amp;author=C+Hindsberger&amp;author=R+Robson&amp;author=M+Zdravkovic&amp;title=Effect+of+renal+impairment+on+the+pharmacokinetics+of+the+GLP-1+analogue+liraglutide." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R34R" class="tab-link-return ref__number"><span class="label">34. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B</person-group>; EMPA-REG OUTCOME Investigators. <span class="references__article-title">Empagliflozin and progression of kidney disease in type 2 diabetes.</span><span class="references__source"><strong>N Engl J Med</strong></span>. <span class="references__year">2016</span>; 375:323–334. doi: 10.1056/NEJMoa1515920<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_35_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1056%2FNEJMoa1515920" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_35_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=27299675" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=375&amp;publication_year=2016&amp;pages=323-334&amp;journal=N+Engl+J+Med&amp;author=C+Wanner&amp;author=SE+Inzucchi&amp;author=JM+Lachin&amp;author=D+Fitchett&amp;author=M+von+Eynatten&amp;author=M+Mattheus&amp;author=OE+Johansen&amp;author=HJ+Woerle&amp;author=UC+Broedl&amp;author=B+Zinman&amp;title=Empagliflozin+and+progression+of+kidney+disease+in+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R35R" class="tab-link-return ref__number"><span class="label">35. </span></a>FDA. <span class="references__article-title">Jardiance (empagliflozin) prescribing information.</span><span class="references__year">2015</span>. <a class="references__uri" href="http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf">http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf</a>. Accessed March 14, 2018.<span class="references__suffix"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2015&amp;title=Jardiance+%28empagliflozin%29+prescribing+information." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R36R" class="tab-link-return ref__number"><span class="label">36. </span></a>FDA. <span class="references__article-title">Invokana (canagliflozin) prescribing information.</span><span class="references__year">2013</span>. <a class="references__uri" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdf</a>. Accessed March 14, 2018.<span class="references__suffix"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2013&amp;title=Invokana+%28canagliflozin%29+prescribing+information." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R37R" class="tab-link-return ref__number"><span class="label">37. </span></a>EMA. <span class="references__article-title">Victoza summary of opinion (post authorisation).</span><span class="references__year">2017</span>. <a class="references__uri" href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001026/human_med_001137.jsp&amp;mid=WC0b01ac058001d124">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001026/human_med_001137.jsp&amp;mid=WC0b01ac058001d124</a>. Accessed March 14, 2018.<span class="references__suffix"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2017&amp;title=Victoza+summary+of+opinion+%28post+authorisation%29." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R38R" class="tab-link-return ref__number"><span class="label">38. </span></a>ADA. <span class="references__article-title">9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018.</span><span class="references__source"><strong>Diabetes Care</strong></span>. <span class="references__year">2018</span>; 41(Suppl1):S86–S104. doi: 10.2337/dc18-S009<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_39_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.2337%2Fdc18-S009" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_39_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=29222380" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=41&amp;publication_year=2018&amp;pages=S86-S104&amp;journal=Diabetes+Care&amp;title=9.+Cardiovascular+disease+and+risk+management%3A+standards+of+medical+care+in+diabetes%E2%80%942018." target="_blank">Google Scholar</a></span></span></li>
<li class="
                references__item
            "><span xmlns:xje="java:com.atypon.publish.util.xml.XslJavaExtension" xmlns:fn="http://www.w3.org/2005/xpath-functions" class="references__note"><a href="#R39R" class="tab-link-return ref__number"><span class="label">39. </span></a><person-group xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://www.niso.org/standards/z39-96/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bkstg="http://www.atypon.com/backstage-ns" person-group-type="author">Standl E, Schnell O, McGuire DK, Ceriello A, Ryden L</person-group>. <span class="references__article-title">Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.</span><span class="references__source"><strong>Lancet Diabetes Endocrinol</strong></span>. <span class="references__year">2017</span>; 5:391–402. doi: 10.1016/S2213-8587(17)30033–5<span class="references__suffix"><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_40_2&amp;dbid=16&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=10.1016%2FS2213-8587%2817%2930033-5" onclick="newWindow(this.href);return false" target="_blank">Crossref</a><a href="https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_4_40_2&amp;dbid=8&amp;doi=10.1161%2FCIRCULATIONAHA.118.036418&amp;key=28131656" onclick="newWindow(this.href);return false" target="_blank">Medline</a><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=5&amp;publication_year=2017&amp;pages=391-402&amp;journal=Lancet+Diabetes+Endocrinol&amp;author=E+Standl&amp;author=O+Schnell&amp;author=DK+McGuire&amp;author=A+Ceriello&amp;author=L+Ryden&amp;title=Integration+of+recent+evidence+into+management+of+patients+with+atherosclerotic+cardiovascular+disease+and+type+2+diabetes." target="_blank">Google Scholar</a></span></span></li>
</ul>
</div>
</div>
